EFSA NDA Panel (EFSA Panel on Dietetic Products, Nutrition and Allergies), 2015. Scientific Opinion on Dietary Reference Values for phosphorus

Tetens, Inge; EFSA Journal

Link to article, DOI: 10.2903/j.efsa.2015.4185

Publication date: 2015

Document Version
Publisher's PDF, also known as Version of record

Link back to DTU Orbit

Citation (APA):

General rights
Copyright and moral rights for the publications made accessible in the public portal are retained by the authors and/or other copyright owners and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with these rights.

- Users may download and print one copy of any publication from the public portal for the purpose of private study or research.
- You may not further distribute the material or use it for any profit-making activity or commercial gain
- You may freely distribute the URL identifying the publication in the public portal

If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately and investigate your claim.
SCIENTIFIC OPINION

Scientific Opinion on Dietary Reference Values for phosphorus

EFSA Panel on Dietetic Products, Nutrition and Allergies (NDA)

European Food Safety Authority (EFSA), Parma, Italy

ABSTRACT

Following a request from the European Commission, the Panel on Dietetic Products, Nutrition and Allergies derived Dietary Reference Values (DRVs) for phosphorus. The Panel considered data from balance studies, losses of phosphorus from the body and intestinal absorption for possible use in a factorial approach, and studies on phosphorus intake and long-term health outcomes. The Panel concluded that these data were insufficient for setting DRVs for phosphorus. Data on the calcium to phosphorus ratio in bones of healthy adults, adjusted for the proportion of phosphorus found outside bone, and data on whole-body calcium and phosphorus contents in Caucasian adults indicate that the calcium to phosphorus molar ratio in the body ranges from 1.4:1 to 1.9:1. Although the fractional absorption of phosphorus is higher than that of calcium, the Panel considered that the actual amounts of calcium and phosphorus that are available for absorption from the diet cannot be determined; therefore, the whole-body calcium to phosphorus ratio was used to set DRVs. The data were considered insufficient to derive Average Requirements and Population Reference Intakes. Based on the DRVs for calcium and considering a molar calcium to phosphorus ratio of 1.4:1 to 1.9:1, amounts of phosphorus were calculated. The Panel chose the lower bound of this range (a ratio of 1.4:1, which results in a higher phosphorus intake value) for setting an Adequate Intake (AI), taking into account estimated phosphorus intakes in Western countries, which are considerably higher than the values calculated. The AI is 160 mg/day for infants (7–11 months) and between 250 and 640 mg/day for children. For adults, the AI is 550 mg/day. Taking into consideration adaptive changes in phosphorus metabolism that occur during pregnancy and lactation, it was considered that the AI for adults also applies to pregnant and lactating women.

KEY WORDS

phosphorus, calcium, molar ratio, Adequate Intake, Dietary Reference Value
SUMMARY
Following a request from the European Commission, the EFSA Panel on Dietetic Products, Nutrition and Allergies (NDA) was asked to deliver a Scientific Opinion on Dietary Reference Values (DRVs) for the European population, including phosphorus.

Phosphorus is involved in many physiological processes, such as in the cell’s energy cycle, in regulation of the body’s acid–base balance, as a component of the cell structure, in cell regulation and signalling, and in the mineralisation of bones and teeth. About 85% of the body’s phosphorus is in bones and teeth, 14% is in soft tissues, including muscle, liver, heart and kidney, and only 1% is present in extracellular fluids. Phosphorus homeostasis is intricately linked to that of calcium because of the actions of calcium-regulating hormones, such as parathyroid hormone (PTH) and 1,25-dihydroxy-vitamin D (1,25(OH)2D), at the level of the bone, the gut and the kidneys.

Phosphorus absorption occurs through passive diffusion and sodium-dependent active transport and via paracellular and cellular pathways. In adults, limited data suggest that net phosphorus absorption ranges from 55 to 80% of intake. Phosphorus absorption is affected by the total amount of phosphorus in the diet and also by the type of phosphorus (organic versus inorganic), the food origin (animal-versus plant-derived) and the ratio of phosphorus to other dietary components. Absorption is regulated by 1,25(OH)2D and PTH.

Hypophosphataemia, defined by a serum inorganic phosphorus concentration of < 0.80 mmol/L (2.48 mg/dL), only rarely occurs because of inadequate dietary phosphorus intake, and is generally due to metabolic disorders.

The major dietary contributors to phosphorus intake are foods high in protein content, i.e. milk and milk products followed by meat, poultry and fish, grain products and legumes. Based on data from 13 dietary surveys in nine European Union countries, mean phosphorus intakes range from 265 to 531 mg/day in infants, from 641 to 973 mg/day in children aged 1 to < 3 years, from 750 to 1 202 mg/day in children aged 3 to < 10 years, from 990 to 1 601 mg/day in children aged 10 to < 18 years and from 1 000 to 1 767 mg/day in adults (≥ 18 years).

Balance studies in adults were considered to be heterogeneous and to have many limitations. Overall, balance studies, including those in children and pregnant women, could not be used for setting DRVs for phosphorus. In addition, it was considered that estimations of phosphorus absorption from the diet, as well as losses of phosphorus via urine and faeces, vary over a wide range, so that the factorial approach cannot be used for deriving the requirement for phosphorus.

Evidence from human studies on the relationship between phosphorus intake and various health outcomes was also reviewed. It was considered that data on measures of bone health, cancer-related outcomes and evidence related to all-cause mortality and cardiovascular outcomes could not be used to derive DRVs for phosphorus.

Data on the molar ratio of calcium to phosphorus in intact bone of healthy adults suggest a range of approximately 1.6:1 to 1.8:1. Using the calcium to phosphorus molar ratio in bone of 1.6:1 to 1.8:1 and adjusting for the proportion of calcium and phosphorus found outside bone, a molar ratio of calcium to phosphorus in the adult body of about 1.37:1 to 1.55:1 is estimated. In addition, data from measurements of whole-body calcium and phosphorus contents in Caucasian men and women indicate that the calcium to phosphorus molar ratio in the whole body ranges from 1.48:1 to 1.69:1 in women and from 1.57:1 to 1.89:1 in men. The Panel thus considered that the ratio of calcium to phosphorus in the whole body ranges from about 1.4:1 to 1.9:1 and proposed, in the absence of other consistent evidence, that DRVs for phosphorus be set based on the approximate molar ratio of calcium to phosphorus in the body. The fractional absorption of phosphorus is higher than that of calcium. However, as phosphorus absorption has been reported to vary over a wide range, it was considered that the actual amounts of calcium to phosphorus that are available for absorption from the diet and
that may be retained in the body cannot be determined. In the absence of this information, the Panel proposed to set DRVs for phosphorus based solely on the range of the molar ratio of calcium to phosphorus in the whole body. The Panel considered that the data are insufficient to derive Average Requirements and Population Reference Intakes (PRIs) for phosphorus and proposed to set Adequate Intakes (AIs) for all population groups. Based on the AI (for infants aged 7–11 months) and the PRIs (for all other ages) for calcium and considering a molar calcium to phosphorus ratio of 1.4:1 to 1.9:1, adequate quantities of phosphorus were calculated in mg/day. The Panel chose the lower bound of this range (i.e. a ratio of 1.4:1 which results in the higher phosphorus intake value) for setting an AI for phosphorus, taking into account estimated phosphorus intakes in Western countries which are considerably higher than the calculated values.

The AI is 160 mg/day for infants aged 7–11 months and between 250 mg/day and 640 mg/day for children. For adults, the AI is 550 mg/day. Taking into consideration adaptive changes in phosphorus metabolism that may occur during pregnancy and lactation, it was considered that the AI for adults also applies to pregnant and lactating women.
TABLE OF CONTENTS

Abstract ........................................................................................................................................... 1
Summary ........................................................................................................................................... 2
Background as provided by the European Commission ................................................................. 6
Terms of reference as provided by the European Commission ..................................................... 6
Assessment ....................................................................................................................................... 8
1. Introduction ................................................................................................................................. 8
2. Definition/category ..................................................................................................................... 8
   2.1. Chemistry............................................................................................................................. 8
   2.2. Function of phosphorus ....................................................................................................... 8
      2.2.1. Biochemical functions ................................................................................................. 8
      2.2.2. Health consequences of deficiency and excess ........................................................... 9
      2.2.2.1. Deficiency ............................................................................................................... 9
      2.2.2.2. Excess .................................................................................................................... 9
   2.3. Physiology and metabolism ................................................................................................ 10
      2.3.1. Intestinal absorption .................................................................................................... 10
      2.3.2. Transport in blood ....................................................................................................... 11
      2.3.3. Distribution to tissues .................................................................................................. 11
      2.3.3.1. Ratio of calcium to phosphorus in the bone and whole body ................................ 12
      2.3.4. Storage ....................................................................................................................... 12
      2.3.5. Metabolism ................................................................................................................. 13
      2.3.6. Elimination .................................................................................................................. 13
      2.3.6.1. Urine ....................................................................................................................... 13
      2.3.6.2. Faeces ...................................................................................................................... 14
      2.3.6.3. Sweat ....................................................................................................................... 14
      2.3.6.4. Breast milk .............................................................................................................. 14
      2.3.7. Interaction with other nutrients .................................................................................... 15
   2.4. Biomarkers .......................................................................................................................... 15
      2.4.1. Biomarkers of intake .................................................................................................... 15
      2.4.1.1. Serum/plasma phosphorus concentration .............................................................. 15
      2.4.1.2. Urinary phosphorus excretion ................................................................................ 16
      2.4.2. Biomarkers of status .................................................................................................... 16
      2.4.2.1. Serum/plasma phosphorus concentration .............................................................. 16
      2.4.2.2. Urinary phosphorus concentration ......................................................................... 17
      2.4.2.3. Serum parathyroid hormone (PTH) ....................................................................... 17
      2.4.2.4. Other biomarkers .................................................................................................... 17
      2.4.2.5. Conclusions on biomarkers of phosphorus intake and status ................................ 17
   2.5. Effects of genotypes ............................................................................................................. 17
3. Dietary sources and intake data ................................................................................................. 18
   3.1. Dietary sources .................................................................................................................... 18
   3.2. Dietary intake ....................................................................................................................... 18
4. Overview of Dietary Reference Values and recommendations .................................................. 20
   4.1. Adults .................................................................................................................................. 20
   4.2. Infants and children ............................................................................................................ 22
   4.3. Pregnancy ........................................................................................................................... 24
   4.4. Lactation .............................................................................................................................. 25
5. Criteria (endpoints) on which to base Dietary Reference Values ................................................ 26
   5.1. Indicators of phosphorus requirement ............................................................................... 26
   5.2. Balance studies on phosphorus ......................................................................................... 26
      5.2.1. Balance studies in adults ............................................................................................ 26
      5.2.2. Balance studies in children ........................................................................................ 28
      5.2.3. Balance studies in pregnancy ..................................................................................... 29
   5.3. Phosphorus requirements in pregnancy and lactation ....................................................... 29
   5.4. Phosphorus intake and health consequences ..................................................................... 29
Dietary Reference Values for phosphorus

5.4.1. Bone health

5.4.1.1. Dietary calcium to phosphorus ratio in relation to bone health

5.4.2. Cancer

5.4.2.1. Prostate cancer

5.4.2.2. Other types of cancer

5.4.2.3. Conclusions on cancer-related outcomes

5.4.3. Cardiovascular disease-related outcomes and all-cause mortality

5.4.3.1. Left ventricular mass

5.4.3.2. Hypertension

5.4.3.3. Conclusions on cardiovascular disease-related outcomes and all-cause mortality

6. Data on which to base Dietary Reference Values

6.1. Adults, infants aged 7–11 months and children

6.2. Pregnancy and lactation

Conclusions

Recommendations for research

References

Appendices

Appendix A. Dietary surveys in the EFSA Comprehensive European Food Consumption Database included in the nutrient intake calculation and number of subjects in the different age classes

Appendix B. Phosphorus intake in males in different surveys according to age classes and country

Appendix C. Phosphorus intake in females in different surveys according to age classes and country

Appendix D. Minimum and maximum percentage contribution of different food groups (FoodEx2 level 1) to phosphorus intake in males

Appendix E. Minimum and maximum percentage contribution of different food groups (FoodEx2 level 1) to phosphorus intake in females

Appendix F. Calculations for deriving Adequate Intakes for phosphorus

Abbreviations
BACKGROUND AS PROVIDED BY THE EUROPEAN COMMISSION

The scientific advice on nutrient intakes is important as the basis of Community action in the field of nutrition, for example such advice has in the past been used as the basis of nutrition labelling. The Scientific Committee for Food (SCF) report on nutrient and energy intakes for the European Community dates from 1993. There is a need to review and, if necessary, to update these earlier recommendations to ensure that the Community action in the area of nutrition is underpinned by the latest scientific advice.

In 1993, the SCF adopted an opinion on the nutrient and energy intakes for the European Community. The report provided Reference Intakes for energy, certain macronutrients and micronutrients, but it did not include certain substances of physiological importance, for example dietary fibre.

Since then new scientific data have become available for some of the nutrients, and scientific advisory bodies in many European Union Member States and in the United States have reported on recommended dietary intakes. For a number of nutrients these newly established (national) recommendations differ from the reference intakes in the SCF (1993) report. Although there is considerable consensus between these newly derived (national) recommendations, differing opinions remain on some of the recommendations. Therefore, there is a need to review the existing EU Reference Intakes in the light of new scientific evidence, and taking into account the more recently reported national recommendations. There is also a need to include dietary components that were not covered in the SCF opinion of 1993, such as dietary fibre, and to consider whether it might be appropriate to establish reference intakes for other (essential) substances with a physiological effect.

In this context EFSA is requested to consider the existing Population Reference Intakes for energy, micro- and macronutrients and certain other dietary components, to review and complete the SCF recommendations, in the light of new evidence, and in addition advise on a Population Reference Intake for dietary fibre.

For communication of nutrition and healthy eating messages to the public it is generally more appropriate to express recommendations for the intake of individual nutrients or substances in food-based terms. In this context the EFSA is asked to provide assistance on the translation of nutrient based recommendations for a healthy diet into food based recommendations intended for the population as a whole.

TERMS OF REFERENCE AS PROVIDED BY THE EUROPEAN COMMISSION

In accordance with Article 29 (1)(a) and Article 31 of Regulation (EC) No. 178/2002, the Commission requests EFSA to review the existing advice of the Scientific Committee for Food on population reference intakes for energy, nutrients and other substances with a nutritional or physiological effect in the context of a balanced diet which, when part of an overall healthy lifestyle, contribute to good health through optimal nutrition.

In the first instance EFSA is asked to provide advice on energy, macronutrients and dietary fibre. Specifically advice is requested on the following dietary components:

- Carbohydrates, including sugars;
- Fats, including saturated fatty acids, polyunsaturated fatty acids and monounsaturated fatty acids, trans fatty acids;

---

• Protein;

• Dietary fibre.

Following on from the first part of the task, EFSA is asked to advise on population reference intakes of micronutrients in the diet and, if considered appropriate, other essential substances with a nutritional or physiological effect in the context of a balanced diet which, when part of an overall healthy lifestyle, contribute to good health through optimal nutrition.

Finally, the EFSA is asked to provide guidance on the translation of nutrient based dietary advice into guidance, intended for the European population as a whole, on the contribution of different foods or categories of foods to an overall diet that would help to maintain good health through optimal nutrition (food-based dietary guidelines).
ASSESSMENT

1. Introduction
Phosphorus is an essential nutrient and is involved in many physiological processes, such as in the cell’s energy cycle, in regulation of the body’s acid–base balance, as a component of the cell structure, in cell regulation and signalling, and in the mineralisation of bones and teeth.

In 1993, the Scientific Committee for Food (SCF, 1993) adopted an opinion on nutrient and energy intakes for the European Community and derived for phosphorus a Lowest Threshold Intake, an Average Requirement (AR) and a Population Reference Intake (PRI) for adults. The SCF also set PRIs for infants from 6 months of age, for children and for pregnant and lactating women.

2. Definition/category
In the human body, phosphorus is present in different forms. Serum contains mainly inorganic phosphates (dihydrogen and monohydrogen phosphate), bone contains phosphorus largely in the form of hydroxyapatite, while the soft tissues and extracellular fluids contain organic phosphates in complex with carbohydrates, lipids and proteins (Bansal, 1990). In this Opinion, the term phosphorus is used for consistency and simplicity when referring to its presence in blood or bone.

2.1. Chemistry
Phosphorus is the 11th most abundant element in the earth’s crust. It is a non-metal, solid chemical element and belongs to Group 15 (VA) of the periodic table of the elements. It has the atomic number 15 and an atomic mass of 30.97 Da. Phosphorus has several oxidation states, the most important being +3 and +5 (RSC, 2004; Kalantar-Zadeh et al., 2010; Corbridge, 2013). Phosphorus does not occur in nature as a free element because of its high reactivity, but is found in the form of phosphate minerals. The most abundant form is apatite (and related minerals), i.e. hydroxyapatite (Ca_{10}(OH)_{2}(PO_{4})_{6}), chlorapatite (Ca_{10}Cl_{2}(PO_{4})_{6}) and fluorapatite (Ca_{10}F_{2}(PO_{4})_{6}). There is only one stable phosphorus isotope, that is 31P. There are, however, several radioactive isotopes with highly variable, usually very short, half-lives ranging from a few nanoseconds to a few seconds. Only two radioactive isotopes (32P and 33P) exist long enough to be measured. 32P has a half-life of 14 days and has applications in medicine, industry and in tracer studies. 33P has a half-life of 25 days and it also has tracer applications (Audi et al., 2003).

2.2. Function of phosphorus
2.2.1. Biochemical functions
Phosphorus is the main mineral constituent of bones and one of the most abundant minerals in the body. About 85% of the body’s phosphorus is in bones and teeth, in the form of hydroxyapatite, and together phosphorus and calcium account for around 80–90% of bone composition. Hydroxyapatite forms the mineralised matrix of bone and contributes to the unique biomechanical properties of bone. Phosphorus homeostasis is intricately linked to that of calcium because of the actions of calcium-regulating hormones, such as parathyroid hormone (PTH) and 1,25-dihydroxy-vitamin D (1,25(OH)_{2}D), at the level of the bone, the gut and the kidneys.

The remaining 15% of phosphorus present in the body is integral to diverse functions ranging from the transfer of genetic information to energy utilisation. Phosphorus is a structural component of the nucleic acids DNA and RNA and thus is involved in the storage and transmission of genetic material. It is an essential component of phospholipids (e.g. phosphatidylcholine) that form all membrane bilayers throughout the body. They are essential for optimal brain health and influence brain cell communication processes and receptor functions. Many sugars, proteins and enzymes in the body are phosphorylated, and that process often determines the activity and function of sugars and phosphoproteins. Phosphorus is an integral component of adenosine triphosphate (ATP), the body’s key energy source. Other phosphorylated molecules (e.g. creatine phosphate in muscle) serve as a
rapid source of phosphate for ATP production and energy transduction in substrate metabolism. Many intracellular signalling processes depend on phosphorus-containing compounds such as cyclic adenosine monophosphate (cAMP), cyclic guanosine monophosphate (cGMP) and inositol polyphosphates (e.g. inositol triphosphate (IP3)). Phosphorus, as 2,3-bisphosphoglycerate (also termed 2,3-diphosphoglycerate), plays an important role in the dissociation of oxygen from haemoglobin. Cellular phosphate is the main intracellular buffer and therefore is essential for pH regulation in the human body (O’Brien et al., 2014).

2.2.2. Health consequences of deficiency and excess

2.2.2.1. Deficiency

Phosphorus deficiency presents as hypophosphataemia, i.e. serum phosphorus concentrations below 0.80 mmol/L (2.48 mg/dL) in adults. This occurs only rarely because of inadequate dietary phosphorus intake, and is almost always due to metabolic disorders. Although rare in the general population, the incidence of hypophosphataemia is high in certain sub-groups of patients, such as those with sepsis, chronic alcoholism, major trauma or chronic obstructive pulmonary disease (Gaasbeek and Meinders, 2005; Brunelli and Goldfarb, 2007). Hypophosphataemia may also occur during the management of diabetic ketoacidosis because the administration of insulin drives glucose and phosphorus into cells and causes a rapid fall in serum phosphate concentrations. Mild hypophosphataemia can also occur as a common, generally asymptomatic, consequence of hyperparathyroidism (O’Brien et al., 2014).

The clinical symptoms of hypophosphataemia usually occur when serum phosphorus concentrations fall below 0.3 mmol/L (≈ 1 mg/dL), particularly when this is associated with total body phosphorus depletion. The nature and severity of the clinical symptoms depend on the extent of the phosphorus depletion and are highly variable, depending on the underlying cause and the individual patient’s status (Brunelli and Goldfarb, 2007). At a whole organism level, the effects of hypophosphataemia include anorexia, anaemia, muscle weakness, bone pain, rickets and osteomalacia, increased susceptibility to infection, paraesthesia, ataxia, confusion and even death. The muscle weakness involves, in particular, proximal muscle groups, and when prolonged or severe can lead to muscle fibre degeneration. The skeleton will exhibit either rickets or osteomalacia, depending on growth status. In both, the disorder consists of a failure to mineralise and form growth plate cartilage and bone matrix, together with the impairment of chondroblast and osteoblast function. This functional disturbance both slows osteoid deposition and disturbs the normal maturation process in the hypertrophic zone of the growth plate cartilage (Heaney, 2012).

2.2.2.2. Excess

In 2005, EFSA (2005) concluded that the available data were not sufficient to establish a Tolerable Upper Intake Level (UL) for phosphorus. Adverse effects of excessive phosphorus intake, such as hyperphosphataemia, leading to secondary hyperparathyroidism, skeletal deformations, bone loss and/or ectopic calcification, have been reported in animal studies. However, such effects were not observed in studies in humans, except in patients with end-stage renal disease. Although an increase in serum PTH concentration was found in acute or short-term loading studies, no significant changes could be demonstrated in longer term studies with dosages of up to 3 000 mg/day. In these studies, no evidence was found for effects on markers of bone remodelling. Similarly, no convincing evidence was found to support suggestions that high-phosphorus diets would aggravate the effects of a state of secondary hyperparathyroidism induced by inadequate calcium intake or an inadequate vitamin D status.

Gastro-intestinal symptoms, such as osmotic diarrhoea, nausea and vomiting, were observed in some healthy subjects taking phosphorus (phosphate) supplements with dosages higher than 750 mg/day, but these symptoms were not considered a suitable basis for establishing a UL for phosphorus from all sources (EFSA, 2005).
2.3. Physiology and metabolism

2.3.1. Intestinal absorption

Phosphorus is absorbed with high efficiency. In adults, net phosphorus absorption typically ranges from 55 to 80% of customary intakes, and in infants from 65 to 90% (Heaney, 2012; O’Brien et al., 2014). Intestinal phosphorus absorption tends to decrease with ageing. Within the gut lumen, phosphatases hydrolyse the organic forms to release inorganic phosphate. Inorganic phosphate is absorbed along the entire intestine, with most being absorbed by the small intestine (Sabbagh et al., 2011). Dietary phosphorus, 1,25(OH)₂D and PTH are thought to be the most important physiological regulators of intestinal phosphorus absorption, although epidermal growth factor, glucocorticoids, oestrogens, metabolic acidosis, phosphatonin and secreted frizzled-related protein 4 (sFRP-4) also affect intestinal phosphorus absorption (Penido and Alon, 2012).

There are two pathways for intestinal absorption of inorganic phosphorus, i.e. paracellular and cellular (Sabbagh et al., 2011; Penido and Alon, 2012), and at least two mechanisms, i.e. passive diffusion (McHardy and Parsons, 1956) and sodium-dependent active transport (Walton and Gray, 1979; Eto et al., 2006). Most phosphorus absorption occurs in the small intestine by load-dependent passive absorption. Paracellular absorption occurs at tight junctions and utilises electrochemical gradients. These are thought to be regulated by signal transduction pathways but the specific mechanism for phosphate has not yet been identified (Sabbagh et al., 2011). Cellular absorption requires sodium-dependent phosphate transporters, which include NaPi-IIa (SLC34A1), NaPi-IIb (SLC34A2 or NPT2b) and NaPi-IIc (SLC34A3), that are also expressed in the renal tubule; however, it is NaPi-IIb that is predominant in the intestine (Penido and Alon, 2012; Biber et al., 2013). The relative proportion of absorption via each mechanism varies depending on the luminal phosphate concentration, with active transport contributing to between 30 and 80% (Sabbagh et al., 2011).

The sodium-dependent phosphate transporter NaPi-IIb can be modulated by low dietary inorganic phosphorus, several hormones and vitamin D (Segawa et al., 2004; Forster et al., 2011; Sabbagh et al., 2011), and the mucosa of the duodenum is particularly responsive to low inorganic phosphorus intake (Marks et al., 2010). Administration of 1,25(OH)₂D to vitamin D-deficient animals resulted in up-regulation of transporters and significantly increased inorganic phosphate absorption (Katai et al., 1999; Kido et al., 2013). Despite some evidence of an impact of vitamin D on phosphorus absorption in humans (Brickman et al., 1977), the net result is probably small and the actual effect of vitamin D on adult phosphorus absorption under usual conditions and in health remains unclear (Heaney, 2012). The small intestine and kidneys work together to maintain circulating levels of inorganic phosphorus (Marks et al., 2010; Biber et al., 2013), although the exact mechanism of how phosphorus is “sensed” has not yet been identified (Bergwitz and Jüppner, 2011). In view of earlier studies identifying the continuation of intestinal phosphorus absorption even in the presence of high blood concentrations of phosphorus (Brickman et al., 1974; IOM, 1997), it is unclear whether or not this regulation may be overwhelmed by high dietary intake.

The ability to absorb and use phosphorus is affected by the total amount of phosphorus in the diet and also by the type of phosphorus (organic versus inorganic), the food origin (animal- versus plant-derived) and the ratio of phosphorus to other dietary components. Most food phosphorus is in the form of readily hydrolysable organic phosphate esters, with the exception of seed foods and unleavened breads. In fact, phytic acid (the storage form of phosphorus in plants) cannot be digested because humans lack the enzyme phytase. Colonic bacteria, which do possess phytase, are able to release some of that phosphorus for absorption. In addition, yeasts can hydrolyse phytic acid and, hence, leavened cereal-grain foods (e.g. many breads) exhibit good phosphorus bioavailability (Heaney, 2012). Apart from phytate, the principal factor influencing phosphorus absorption is co-ingested calcium, which binds phosphorus in the digestive chime, thereby preventing its absorption (Heaney, 2012; O’Brien et al., 2014). In two human metabolic balance studies with a total of 566 measurements from 284 subjects, Heaney and Nordin (2002) showed that calcium intake is the main dietary determinant of phosphorus absorption. Based on 470 measurements from 191 women, the authors estimated that each
increase in calcium intake of 0.5 g (12.5 mmol) decreases phosphorus absorption by 0.166 g (5.4 mmol). Phosphorus originating from food additives, i.e. already in an ionised inorganic form, is absorbed more readily than organic phosphorus naturally occurring in animal and plant foods (Kalantar-Zadeh et al., 2010).

The Panel notes that phosphorus absorption from the diet has been reported to vary over a wide range.

2.3.2. Transport in blood

Phosphorus is present in the blood in both organic and inorganic forms. Approximately 70% of phosphorus in the blood is in the form of organic compounds, including phospholipids, i.e. in blood cell membranes and plasma lipoproteins. Of the remaining 30%, most (∼85%) is present as inorganic phosphorus, while a small percentage is found complexed with sodium, calcium and magnesium as salts in the blood.

In plasma, the phosphate ions HPO$_4^{2-}$ and H$_2$PO$_4^-$ exist in a pH-dependent equilibrium. About 85–90% of serum phosphate is free and is ultrafiltrable; 10–15% is bound to protein. The normal concentration of phosphate in human serum/plasma is 0.8–1.5 mmol/L, which is maintained within this physiological range by regulation of dietary absorption, bone formation and renal excretion, as well as equilibration with intracellular stores. Serum phosphorus concentration fluctuates with age (it is higher in children than in adults), acid–base status and dietary intake (Marks et al., 2010) (see Section 2.4.1.1). The increased serum phosphorus concentration following ingestion of phosphorus then depresses the serum calcium ion (Ca$^{2+}$) concentration, which in turn stimulates the parathyroid glands to synthesise and secrete PTH. PTH acts on bone and the kidneys to correct the modest decline in Ca$^{2+}$ and homeostatically return it to the required level. It has been suggested that an elevation of serum phosphorus ionic concentration directly influences PTH secretion independently of hypocalcaemia (O’Brien et al., 2014). These meal-associated fluctuations in phosphorus and Ca$^{2+}$ are part of normal physiological adjustments that occur typically three or more times a day. The blood concentration of phosphorus is less tightly regulated than the serum calcium concentration. Wider fluctuations in serum phosphorus concentration reflect both dietary intake and cellular release of inorganic phosphates (Anderson, 2005). There is diurnal variation (Jubiz et al., 1972; Moe et al., 2011), with values being lowest in the early morning and rising during the day (Pocock et al., 1989).

2.3.3. Distribution to tissues

Phosphorus, as phosphate, is the most abundant anion in the human body and comprises approximately 1% of total body weight (Farrow and White, 2010; Penido and Alon, 2012). Approximately 85% of phosphorus is present in bones and teeth, with the remainder distributed among other tissues (14%) and extracellular fluid (1%) (O’Brien et al., 2014). Thus, like calcium (although more pronounced), serum measurements reflect only a minor fraction of total body phosphorus, and therefore do not consistently reflect total body stores (Moe, 2008). Intracellular phosphorus exists in the form of organic compounds such as ATP and as free phosphate anions (e.g. PO$_4^{3-}$) (Takeda et al., 2012). Cells hold very limited reserves of inorganic phosphorus and rely on supplies from extracellular fluid (IOM, 1997). In bone, phosphorus is primarily complexed with calcium in the form of hydroxyapatite crystals; the remaining phosphate appears as amorphous calcium phosphate (Farrow and White, 2010). In soft tissue and cell membranes, phosphorus exists mainly as phosphate esters and to a lesser extent as phosphoproteins and free phosphate ions. In the extracellular fluid, about one-tenth of the phosphorus content is bound to proteins, one-third is complexed to sodium, calcium and magnesium, and the remainder is present as inorganic phosphorus (Penido and Alon, 2012).

In pregnancy, especially in the third trimester, inorganic phosphorus moves from the mother to the fetus against a concentration gradient (Brunette et al., 1986; Husain and Mughal, 1992). This is a sodium-dependent, energy-requiring process facilitated by NaPi-IIb (SLC34A2) transporters, which are expressed in the placental labyrinthine cells (Mitchell and Jüppner, 2010). The placenta meets the fetal need by actively transporting phosphorus from the maternal circulation. Phosphorus is
maintained in the fetal circulation at higher concentrations than in the mother, and such high levels appear necessary for the developing skeleton to accrete a normal amount of phosphorus by term. However, the factors and the molecular mechanism controlling placental phosphorus transport have not yet been explored (Mitchell and Jüppner, 2010; Kovacs, 2014). Phosphorus rises over the first 24–48 hours after delivery; after that, it declines towards adult values, consistent with resolution of transient hypoparathyroidism in the newborn (Kovacs, 2014).

2.3.3.1. Ratio of calcium to phosphorus in the bone and whole body

Calcium and phosphorus are both required for bone mineral deposition and maintenance throughout life. The calcium to phosphorus ratio in bone has been measured using instrumental neutron activation analysis. Measurement of intact bone of 37 females and 45 males aged 15–55 years showed a mean calcium to phosphorus mass ratio of 2.33:1 ± 0.34:1 (range 2.05:1 to 2.62:1) in rib bone (Tzaphlidou and Zaichick, 2002), 2.17:1 ± 0.31:1 in cortical bone (Zaichick and Tzaphlidou, 2002) and 2.07:1 ± 0.23:1 (range 1.55:1 to 2.72:1) in trabecular bone of the femoral neck (Zaichick and Tzaphlidou, 2003). These mean mass ratios of calcium to phosphorus measured in different skeletal sites are equivalent to mean molar ratios of 1.6:1 to 1.8:1 in the bone of healthy adolescents and adults.

The Panel notes that, while the majority (99%) of body calcium is in bone (EFSA NDA Panel, 2015), about 15% of body phosphorus is outside bone as a key functional component in other tissues (14%) and extracellular fluid (1%) (Section 2.3.3). Thus, using the calcium to phosphorus molar ratio in bone of 1.6:1 to 1.8:1 and adjusting for the amount of phosphorus outside bone, a molar ratio of calcium to phosphorus in the adult body of about 1.37:1 to 1.55:1 (1.6:1 divided by 0.99:0.85 to 1.8:1 divided by 0.99:0.85) may be estimated.

Outside the skeleton, phosphorus and calcium have essential and distinct physiological functions which are mediated independently and separately by specific transporters, the precise regulation of which, in the case of phosphorus, has not been fully elucidated.

Using total body neutron activation analysis, Ellis (1990) measured whole-body contents of calcium and phosphorus in 1134 Caucasian women aged between 20 and 74 years and in 175 Caucasian men aged between 20 and 90 years in the USA. From these, mass ratios may be calculated that range from 1.92:1 to 2.18:1 according to age in women, and from 2.04:1 to 2.44:1 in men. These mass ratios are equivalent to molar ratios of calcium to phosphorus in the whole body of 1.48:1 to 1.69:1 in women and 1.57:1 to 1.89:1 in men.

Taking into account the molar calcium to phosphorus ratio in the whole body estimated from the molar ratio of calcium to phosphorus in bone and the observations of Ellis (1990), the Panel considers that the ratio of calcium to phosphorus in the whole body ranges from about 1.4:1 to 1.9:1. The Panel notes the absence of specific data for infants and children up to 15 years of age.

2.3.4. Storage

Total body phosphorus in adults has been reported to be in the order of 400–800 g, and most of this is located in the bones and teeth (Moe, 2008). Using total body neutron activation analysis, total body phosphorus (mean ± standard deviation (SD)) ranged from 374 ± 60 g to 439 ± 70 g in 1134 Caucasian women aged between 20 and 74 years and from 461 ± 82 g to 561 ± 69 g in 175 Caucasian men aged between 20 and 90 years in the USA (Ellis, 1990).

At birth, a neonate contains roughly 20 g phosphorus (0.5 g/100 g fat free tissue), most of which is accumulated during the last 8 weeks of pregnancy (Widdowson and Spray, 1951). Assuming continuous growth and maturity at 18 years, it has been estimated that continuous phosphorus accretion rates are 107 mg/day in boys and 80 mg/day in girls, with a peak rate in adolescence of 214 mg/day, while at age 4–12 months, accretion rates of 66 mg/day have been estimated (Prentice and Bates, 1994).
2.3.5. Metabolism

The absorbed phosphorus enters the exchangeable phosphorus pool which consists of the intracellular phosphorus (70%), the phosphorus arising from bone remodelling (29%) and the phosphorus in serum (< 1%). Exit from the exchangeable pool is through skeletal deposition, renal excretion and intestinal secretion. Under physiological conditions in adults, the amount of phosphorus entering the phosphorus pool from bone resorption equals that exiting the pool for bone formation (Hruska et al., 2008). Both the intestine and the kidneys are involved in phosphate homeostasis by serving as regulators of phosphorus absorption from the diet (in the inorganic form) and phosphorus excretion (in the inorganic form), respectively (Berndt and Kumar, 2007).

Phosphorus homeostasis is tightly regulated by the bone–kidney–parathyroid gland axis. The key hormones contributing to the regulation of phosphorus homeostasis are PTH, the active metabolite of vitamin D (i.e. 1,25(OH)₂D) and the phosphatonin fibroblast growth factor-23 (FGF-23), mainly produced and secreted by osteocytes in bone (Berndt and Kumar, 2009; Bergwitz and Jüppner, 2010). An elevation in serum phosphorus concentration as a result of a diet high in phosphorus leads to a decrease in serum calcium concentration and an increase in PTH release resulting in increased renal phosphate excretion. The increase in serum inorganic phosphate additionally results in a reduced 1,25(OH)₂D synthesis which in turn leads to a reduced intestinal phosphorus absorption (Berndt and Kumar, 2009; Bergwitz and Jüppner, 2010). An increase in serum phosphorus concentration also results in an increased secretion of FGF-23 by the osteocytes which directly stimulates the renal fractional excretion of phosphorus and induces a reduction in the 1,25(OH)₂D concentration, with a subsequent decrease in intestinal phosphorus absorption (Quarles, 2008). On the other hand, a decrease in serum phosphorus concentration as a result of a diet low in phosphorus leads to an increase in serum calcium concentration and a decrease in PTH release resulting in decreased renal phosphorus excretion. Additionally, a decrease in serum phosphorus concentration leads to an increased 1,25(OH)₂D synthesis and subsequent enhanced phosphorus absorption by the intestine (Berndt and Kumar, 2009; Bergwitz and Jüppner, 2010). Finally, a decrease in serum phosphorus concentration reduces serum FGF-23, thus restoring the concentration of serum phosphorus (Quarles, 2008).

2.3.6. Elimination

2.3.6.1. Urine

The kidney plays a predominant role in the regulation of systemic phosphorus homeostasis. About 80% of filtered phosphorus is reabsorbed in the proximal tubule. There is likely to be no reabsorption of phosphorus in the loop of Henle and the collecting duct. Some evidence has been provided that in distal nephron segments approximately 5% of filtered phosphorus may be reabsorbed. Under normal conditions, about 15% of the filtered phosphorus is ultimately excreted (Bindels et al., 2012). When an individual is in phosphorus equilibrium (i.e. not gaining or losing phosphorus), the amount of phosphorus excreted in the urine (1–1.5 g/24 hours) is equivalent to the amount of phosphorus absorbed in the intestine (Berndt and Kumar, 2007). The tubular reabsorption of phosphorus is saturable, that is, when the serum phosphorus concentration exceeds the renal threshold, phosphorus begins to appear in the urine, increasing in proportion to the filtered load (Bindels et al., 2012).

The reabsorption of inorganic phosphorus in the kidney occurs along with sodium via specific sodium phosphate co-transporters (Tenenhouse and Murcr, 2003). The main transporter involved in this process is NaPi-IIa (Tenenhouse, 2005). Controlling the numbers of this transporter leads to regulation of phosphorus reabsorption in the kidney. Factors that increase tubular phosphorus reabsorption include low intake of phosphorus and high intake of potassium, parathyroidectomy, 1,25(OH)₂D₃, hypocalcaemia, volume contraction and hypocapnia (i.e. a state of reduced carbon dioxide in the blood), whereas factors that decrease phosphorus tubular reabsorption include a diet high in phosphorus and low in potassium, PTH, volume expansion, hypercalcaemia, carbonic anhydrase inhibitors, glucose and alanine, acid–base disturbances, increased bicarbonate, hypocalcapnia, metabolic inhibitors, FGF-23 and sFRP-4 (Schiavi and Kumar, 2004; Berndt and Kumar, 2009). FGF-23, along with PTH, regulates the reabsorption of phosphorus at the level of the renal proximal tubule. Studies in
healthy volunteers showed that the secretion of FGF-23 reacts to variation in dietary phosphorus intake, increasing under conditions of excess dietary intake and being reduced by dietary phosphorus restriction (Oliveira et al., 2010; Moe et al., 2011; Shigematsu et al., 2012). Other studies indicated that klotho may independently contribute to the regulation of renal phosphorus handling (Hu et al., 2010). Phosphatonin, and in particular FGF-23, and klotho are also postulated to be involved in phosphorus homeostasis in pathophysiological conditions associated with phosphorus wasting.

Clearance studies have demonstrated that phosphorus excretion is remarkably responsive to antecedent dietary phosphorus intake. The phosphorus reabsorption capacity adapts to altered intake of phosphorus within hours (acute adaptation) and remains changed during prolonged intake of altered amounts of dietary phosphorus. Fractional excretion of phosphorus increases with a high phosphorus diet and decreases with a low phosphorus diet (Bindels et al., 2012).

2.3.6.2. Faeces

Faecal excretion of phosphorus has been reported to range from about 300 to 600 mg/day (Greger et al., 1978; Anderson, 2005; Delgado-Andrade et al., 2011). Total faecal phosphorus, however, represents both non-absorbed phosphorus from food, and losses of endogenous phosphorus. The latter are mainly derived from digestive secretions that have not been reabsorbed. The daily faecal loss of endogenous phosphorus is between 0.9 and 4 mg/kg body weight per day (O'Brien et al., 2014).

2.3.6.3. Sweat

Sweat is not an important route of phosphorus loss. Very small quantities of phosphorus in sweat (0.45–0.81 mg/hour) have been reported following a phosphorus-rich meal challenge (Consolazio et al., 1963).

2.3.6.4. Breast milk

The phosphorus concentration of human milk increases during early lactation and then gradually declines with progressing lactation. Atkinson et al. (1995) reported an average phosphorus concentration in human milk of about 160 mg/L at 14 days, 140 mg/L at 30 and 90 days and 120 mg/L at 180 days post partum.

Following a comprehensive literature search for studies published from the year 2000 onwards, five studies were retrieved which reported on the phosphorus concentration of breast milk. Three studies reported phosphorus concentrations of mature milk from women in Europe, whereas the other two studies covered women living in Australia and Mexico and did not report on the stage of lactation. Phosphorus concentrations were (mean ± SD) 172 ± 23 mg/L in 60 women in Sweden after 14–21 days of lactation (Bjorklund et al., 2012), (median (range)) 123.7 (76.9–159.7) mg/L in 10 Caucasian women in the UK after 9–13 weeks of lactation (Nickkho-Amiry et al., 2008), and 130 mg/kg of breast milk (mean) in nine milk samples from Polish women after 5–6 months of lactation (Witczak and Jarnuszewska, 2011).

Gidrewicz and Fenton (2014) published a systematic review and meta-analysis of 41 studies of breast milk composition. Data on the phosphorus concentration of breast milk from mothers of term infants were available from seven studies, and these results are summarised in Table 1 below.
Table 1: Breast milk phosphorus concentration (mg/L) over time in studies with mothers of term infants, according to Gidrewicz and Fenton (2014)

<table>
<thead>
<tr>
<th>Time post partum</th>
<th>Breast milk phosphorus concentration (mg/L)</th>
<th>Mean</th>
<th>SD</th>
<th>n</th>
</tr>
</thead>
<tbody>
<tr>
<td>Day 1–3</td>
<td>110</td>
<td>30</td>
<td>6</td>
<td></td>
</tr>
<tr>
<td>Day 4–7</td>
<td>130</td>
<td>40</td>
<td>86</td>
<td></td>
</tr>
<tr>
<td>Week 2</td>
<td>150</td>
<td>40</td>
<td>90</td>
<td></td>
</tr>
<tr>
<td>Week 3–4</td>
<td>160</td>
<td>30</td>
<td>75</td>
<td></td>
</tr>
<tr>
<td>Week 5–6</td>
<td>160</td>
<td>30</td>
<td>213</td>
<td></td>
</tr>
<tr>
<td>Week 7–9</td>
<td>160</td>
<td>30</td>
<td>363</td>
<td></td>
</tr>
<tr>
<td>Week 10–12</td>
<td>140</td>
<td>30</td>
<td>13</td>
<td></td>
</tr>
</tbody>
</table>

Based on data reported in seven studies also having a group of mothers of term infants (Atkinson et al., 1980; Gross et al., 1980; Sann et al., 1981; Lemons et al., 1982; Butte et al., 1984b; Mataloun and Leone, 2000; Yamawaki et al., 2005). n, number of samples.

The Panel notes that no quantitative assessment of phosphorus resorption from bone during lactation is available. However, extended lactation is associated with a modest reduction in bone mineral density (BMD), with a return to baseline 12 months after parturition (Sowers et al., 1993; Karlsson et al., 2001), independently of the length of lactation (Moller et al., 2012). The role of dietary phosphorus during pregnancy and lactation has not been established.

Prentice (2003) reviewed the evidence regarding biological adaptation mechanisms (increases in food intake, elevated gastro-intestinal absorption, decreased mineral excretion and mobilisation of tissue stores) required to preserve the maternal mineral economy while meeting the additional mineral requirements during pregnancy and lactation. This author concluded that both pregnancy and lactation are associated with physiological adaptive changes in mineral metabolism that are independent of maternal mineral supply within the range of normal dietary intakes. These adaptive processes provide the minerals necessary for fetal growth and breast milk production without requiring an increase in maternal dietary intake or compromising maternal bone health in the long term.

The Panel considers that around 140 mg/L (4.5 mmol/L) of phosphorus is secreted with mature human milk. The Panel acknowledges the existence of physiological adaptive processes that ensure sufficient phosphorus for fetal growth and breast milk production. These may obviate the need in pregnancy and lactation for additional phosphorus in the diet, provided intake is close to the Dietary Reference Value (DRV) for adults.

2.3.7. Interaction with other nutrients

Several interactions between phosphorus and calcium have been documented at both the intestinal and renal levels. Phosphate decreases urinary calcium excretion, and increases calcium balance (Fenton et al., 2009). A high phosphorus/low calcium diet and, inversely, a high calcium/low phosphorus diet can result in reduced absorption of the lower dose mineral which can lead to disturbances in calcium or phosphorus homeostasis, with possible detrimental consequences on bone health (EFSA NDA Panel, 2015).

2.4. Biomarkers

2.4.1. Biomarkers of intake

A precise assessment of dietary phosphorus intake in free-living individuals is difficult because of the questionable accuracy of dietary instruments used to estimate phosphorus in foods in all its forms, particularly inorganic sources from phosphorus-based food additives and dietary supplements (Calvo and Uribarri, 2013). Thus, there is a need for surrogate markers of phosphorus intake beyond dietary estimates.
2.4.1.1. Serum/plasma phosphorus concentration

Serum/plasma inorganic phosphorus has been proposed as an indicator of adequacy of phosphorus intake (IOM, 1997), mainly based on the equation proposed by Nordin (1989), derived from data from an infusion study (Bijovet, 1969). This equation was established in adults with normal renal function who were infused with < 20 mmol/day (< 619 mg/day) of phosphorus. The relationship became weaker at higher amounts of infused phosphorus. Since serum phosphorus concentration is maintained within a relatively narrow range by different homeostatic mechanisms (Section 2.3.5), the effect of dietary phosphorus intake on serum phosphorus concentration appears to be relatively small, even in the presence of wide variations in dietary phosphorus intake. The association between dietary phosphorus intake and serum phosphorus concentration in fasting and non-fasting samples from 15,513 participants has been evaluated using data from the Third National Health and Nutrition Examination Survey (NHANES) in the USA (de Boer et al., 2009). Phosphorus intake was assessed by 24-hour dietary recall and 1-month food frequency questionnaire (FFQ). A weak but significant association of dietary phosphorus intake with serum phosphorus concentration was observed, with each 500-mg/day increment in phosphorus intake being associated with an increase of 0.03 mg/dL in serum phosphorus, after adjustment for confounders. The Panel notes that this represents about 1 % of the usual serum phosphorus concentration. A smaller study conducted in Spain showed no association between dietary phosphorus intake (25th–75th percentile intake in men and women, 952–1,511 mg/day and 826–1,315 mg/day, respectively) and serum phosphorus concentration (Mataix et al., 2006). A possible explanation for these weak and inconsistent findings is that the renal clearance of plasma phosphorus is so finely regulated that fasting serum/plasma phosphorus concentration shows only minimal changes even in the presence of wide variations in intake. In most observational studies, serum phosphorus concentration was measured in only fasting morning samples, while detailed feeding studies showed that changes in the order of 0.5–1.0 mg/dL in serum phosphorus related to phosphorus loading or restriction may be detected only by serial measurements of serum phosphorus concentration throughout the day and subsequently averaging the concentrations measured throughout the 24 hours (Portale et al., 1987; Calvo et al., 1988; Kemi et al., 2006). In particular, in six healthy men, a 40 % reduction in the 24-hour mean serum phosphorus concentration, compared with the concentration measured during normal phosphorus intake (1,500 mg/day), occurred during severe phosphorus restriction (500 mg/day for 10 days), while a 14 % increase in the 24-hour mean serum phosphorus concentration was observed during phosphorus loading (3,000 mg/day for 10 days). Fasting serum phosphorus concentrations were unmodified during both restriction and loading periods compared with the control period (Portale et al., 1987).

The Panel notes that serum phosphorus concentration cannot be considered a reliable marker of intake as it increases for a short period after ingestion of a meal and then decreases and remains within a relatively narrow range as a result of homeostatic mechanisms. Moreover, because of fine renal regulation, fasting serum phosphorus concentration shows only minimal modifications even in the presence of wide variations in intake.

2.4.1.2. Urinary phosphorus excretion

Under normal conditions, the main excretory route of phosphorus from the body is through the kidney (see Section 2.3.6.1). Although urinary phosphorus excretion generally reflects dietary intake, it is regulated by a number of factors which limits its use as biomarker of intake.

2.4.2. Biomarkers of status

2.4.2.1. Serum/plasma phosphorus concentration

Serum inorganic phosphorus is the most commonly used indicator of phosphorus status; however, it generally inadequately reflects body stores. Only 1 % of total body phosphorus is found in extracellular fluid, and serum/plasma inorganic phosphorus concentrations typically range from 0.8–1.5 mmol/L in adults (Greenberg et al., 1960; IOM, 1997), irrespective of dietary phosphorus intake or whole-body phosphorus content/status. Serum phosphorus concentrations are influenced by age, sex,
lactation, diurnal and seasonal variations, vitamin D status and pathological conditions such as malabsorption syndromes and insulin-dependent diabetes mellitus (Gibson, 2005).

2.4.2.2. Urinary phosphorus concentration

Urinary phosphorus concentration generally reflects dietary intake under normal conditions, as urine is the main excretory route. However, concentrations are affected by a whole range of other factors which impact on calcium and phosphorus metabolism (see Section 2.3.6.1). Therefore, urinary phosphorus is of limited use as biomarker of phosphorus status.

2.4.2.3. Serum parathyroid hormone (PTH)

PTH is the most important endocrine regulator of calcium and phosphorus concentrations in extracellular fluid. It is secreted from the parathyroid glands and its major sites of action are bone and kidney. However, this hormone is of limited use as biomarker as its concentration is affected by vitamin D status as well as serum ionised calcium and phosphorus concentrations.

2.4.2.4. Other biomarkers

In addition to PTH, other phosphorus-regulating factors, such as FGF-23 and klotho, a protein present both in membranes and in circulation and needed for FGF-23 to bind to its receptor, have recently been suggested as possible biomarkers of phosphorus status (see Gutierrez (2013)). However, the Panel considers that there is as yet insufficient information to conclude on the use of these factors as biomarkers of phosphorus status.

2.4.2.5. Conclusions on biomarkers of phosphorus intake and status

The Panel considers that there is currently no reliable biomarker of phosphorus intake and status that may be used for deriving the requirement for phosphorus.

2.5. Effects of genotypes

The understanding of phosphorus homeostasis has largely been obtained from molecular studies of human inherited genetic disorders (Bergwitz and Jüppner, 2010) and acquired disorders (Christov and Jüppner, 2013). Hereditary diseases in phosphorus metabolism and the cloning of the genes leading to these disorders (including urinary phosphate wasting and depletion of phosphorus stores (Alizadeh Naderi and Reilly, 2010)) have provided understanding of the regulation of phosphorus metabolism in both healthy and diseased individuals, and have shown that the osteo–renal metabolic axis plays a large role in phosphorus homeostasis (de Menezes et al., 2006).

Genetic disorders which affect urinary excretion of phosphorus have a major impact on serum phosphorus concentrations. For example, mutations in genes encoding phosphate transporters NPT2 and PiT lead to disturbed phosphorus homeostasis (Prié and Friedlander, 2010). Additionally, hypophosphataemia and hypophosphataemic rickets are caused by mutations in the sodium–phosphate co-transporters NaPi-IIa and NaPi-IIc, respectively (Jüppner, 2007; Pettifor, 2008; Ramasamy, 2008). Elucidation of these mechanisms has identified regulators of phosphorus homeostasis including FGF-23 and a phosphate-regulating gene (PHEX) with homology to endopeptidases on the X-chromosome (Tenenhouse, 2005).

The Panel notes that, although genetic defects leading to a number of rare disorders affecting phosphorus homeostasis have been characterised at the molecular level, no genotypes have been identified that would require consideration with regard to the estimation of DRVs for phosphorus in the general population.
3. Dietary sources and intake data

3.1. Dietary sources

Phosphorus is found in many foods. The major dietary contributors to phosphorus intake are foods high in protein, i.e. milk and milk products followed by meat, poultry and fish, grain products and legumes (Calvo and Uribarri, 2013).

Currently, calcium glycerophosphate, calcium salts of orthophosphoric acid, ferric sodium diphosphate, ferrous ammonium phosphate, ferric diphosphate (ferric pyrophosphate), magnesium glycerophosphate, magnesium salts of orthophosphoric acid, manganese glycercophosphate, sodium salts of orthophosphoric acid, potassium glycercophosphate, potassium salts of orthophosphoric acid, riboflavin 5′-phosphate (sodium) and pyridoxine 5′-phosphate may be added to both foods and food supplements, whereas ferrous phosphate, sodium monofluorophosphate, thiamine monophosphate chloride, thiamine pyrophosphate chloride and pyridoxal 5′-phosphate may only be used in food supplements. The phosphorus content of infant and follow-on formulae is regulated.

The use by the food industry of food additives containing phosphorus is widespread. Most phosphorus-containing additives are inorganic salts of phosphorus that are widely used in the processing of many different foods, ranging from baked goods and restructured meats to cola beverages. However, the amount of phosphorus contributed by the use of phosphorus-containing food additives in processed and prepared foods is difficult to quantify (Calvo and Uribarri, 2013). Data on phosphorus in food composition databases are likely to underestimate the contribution from phosphate-containing additives (Oenning et al., 1988). This is partly because of changes in phosphorus content as the processing and formulation of new food products evolves. The ability to accurately capture dietary intakes is related to the food coverage in the database and the proportion of values based on chemical analysis, as well as to the dietary assessment method used. It has been estimated that phosphorus added during processing can represent an average daily intake of 500 mg/day in the USA, ranging from 300 mg/day to 1 000 mg/day depending on individual food preferences (IOM, 1997).

3.2. Dietary intake

EFSA estimated dietary intakes of phosphorus from food consumption data from the EFSA Comprehensive European Food Consumption Database (EFSA, 2011a), classified according to the food classification and description system FoodEx2 (EFSA, 2011b). Food consumption data from 13 dietary surveys from nine European Union (EU) countries were used. The countries included were Finland, France, Germany, Ireland, Italy, Latvia, the Netherlands, Sweden and the UK. The data covered all age groups from infants to adults aged 75 years and older (Appendix A).

Nutrient composition data for phosphorus were derived from the EFSA Nutrient Composition Database (Roe et al., 2013). Food composition information from Finland, France, Germany, Italy, the Netherlands, Sweden and the UK was used to calculate phosphorus intake in these countries, assuming that the best intake estimate would be obtained when both the consumption data and the composition data are from the same country. For phosphorus intake estimates for Ireland and Latvia, food composition data from the UK and Germany, respectively, were used, because no specific composition data from these countries were available. In the event of missing values in a food composition database, data providers had been allowed to borrow values from another country’s database. The amount of borrowed phosphorus values in the seven composition databases used varied between 15% and amending Directive 2002/46/EC of the European Parliament and of the Council of 10 June 2002 on the approximation of the laws of the Member States relating to food supplements. OJ L 183, 12.7.2002, p. 51.


and 85%. A phosphorus value was missing for all included countries for 665 consumed food items, for which imputation of missing composition values was undertaken by EFSA. Phosphorus intake calculations were performed only on subjects with at least two reporting days. EFSA intake estimates are based on the consumption of foods, either fortified or not (i.e. without consideration of dietary supplements).

Food consumption data of infants (aged 1 to < 12 months in the Italian INRAN-SCAI survey, 4 to < 12 months in the UK DNSIYC survey, 6 months in the Finnish DIPP study and 6 to < 12 months in the German VELS survey, for full names of all surveys, see Abbreviations) were provided by four studies. The consumption of human milk was taken into account if the amount of human milk consumed (Italian INRAN-SCAI survey and UK DNSIYC survey) or the number of breast milk consumption events (German VELS survey) were reported. In the case of the Italian INRAN-SCAI survey, the data provider had estimated the human milk consumption prior to submitting the data to EFSA based on the number of eating occasions using standard portions per eating occasion. In the Finnish DIPP study, only the information “breast fed infants” was available, but without any indication of the number of breast milk consumption events or the amount of breast milk consumed per event. For the German VELS study, the total amount of breast milk was calculated based on the observations by Paul et al. (1988) on breast milk consumption during one eating occasion at different ages, i.e. the amount of breast milk consumed on one eating occasion was set to 135 g/eating occasion for infants aged 6–7 months and to 100 g/eating occasion for infants aged 8–12 months. The Panel notes the limitations in the methods used for assessing breast milk consumption in infants (Appendices B and C) and related uncertainties in the intake estimates for infants.

For both sexes combined, average phosphorus intake ranged from 265 to 531 mg/day (102–154 mg/MJ) in infants (< 1 year of age, four surveys), from 641 to 973 mg/day (149–207 mg/MJ) in children aged 1 to < 3 years (five surveys), from 750 to 1 202 mg/day (133–206 mg/MJ) in children aged 3 to < 10 years (seven surveys), from 990 to 1 601 mg/day (131–196 mg/MJ) in children aged 10 to < 18 years (seven surveys) and from 1 000 to 1 767 mg/day (149–207 mg/MJ) in adults (≥ 18 years) (eight surveys). Average daily intake was, in most cases, slightly higher in males (Appendix B) than in females (Appendix C), mainly because of larger quantities of food consumed per day.

The main food groups contributing to phosphorus intake were milk and dairy products, and grains and grain-based products. In children and adults, milk and dairy products contributed up to about 30–53% to phosphorus intake in the different age classes. Grains and grain-based products contributed up to 27–38% to phosphorus intake. The contribution of meat and meat products was between 10 and 25% in the age groups from 10 years and above. Differences in main contributors to phosphorus intakes between sexes were minor (Appendix D and E).

EFSA’s phosphorus intake estimates in mg/day were compared with published intake values, where available, from the same survey and dataset and the same age class, using the German EsKiMo and VELS surveys in children (Kersting and Clausen, 2003; Mensink et al., 2007), the study in Finnish adolescents (Hoppu et al., 2010), the French INCA2 survey (Afssa, 2009), the Irish NANS (IUNA, 2011), the Finnish FINDIET 2012 Survey (Helldán et al., 2013), the Italian INRAN-SCAI survey (Sette et al., 2011), the Dutch National Food Consumption Survey (van Rossum et al., 2011) and the Swedish national survey Riksmaten (Amcoff et al., 2012) (Table 2). Values below 100% indicate that EFSA’s intake estimates are lower than published values and values above 100% indicate the opposite.
Table 2: EFSA’s average phosphorus intake estimates, expressed as percentages of published intake

<table>
<thead>
<tr>
<th>Country</th>
<th>% of published intake, range over different age classes in a specific survey</th>
</tr>
</thead>
<tbody>
<tr>
<td>Finland</td>
<td>99–100 (Finnish adolescents), 91–93 (FINDIET 2012)</td>
</tr>
<tr>
<td>France</td>
<td>97–102 (INCA2)</td>
</tr>
<tr>
<td>Germany</td>
<td>80–83 (VELS infants), 92–102 (VELS children), 106–111 (EsKiMo)</td>
</tr>
<tr>
<td>Ireland</td>
<td>109–115 (NANS)</td>
</tr>
<tr>
<td>Italy</td>
<td>97–102 (INRAN-SCAI)</td>
</tr>
<tr>
<td>Netherlands</td>
<td>91–93 (Dutch National Food Consumption Survey)</td>
</tr>
<tr>
<td>Sweden</td>
<td>106–112 (Riksmaten)</td>
</tr>
</tbody>
</table>

When the EFSA phosphorus intake estimates were compared with published intake estimates from the same surveys and same age ranges, the EFSA estimates differed by up to about 10% from the published values in four countries (Finland, France, Italy and the Netherlands) and in Germany, except among infants in the German VELS study, where the EFSA intake estimates were lower by 17–20% than published values. One reason for the difference in the intake estimates for VELS seems to be the phosphorus content of the infant and follow-on formulae in the composition databases. For the EFSA intake estimates, the unlikely high phosphorus content of the German formula products were harmonised to comply with the legislation. When comparing the EFSA phosphorus intake estimates with published values for VELS before and after this change, the difference in estimated phosphorus intakes increases from <5% to about 20%.

For the Irish and Swedish surveys, the EFSA intake estimates were higher by about 6–15% than the published values. Overestimation of phosphorus intakes in Ireland may be partly related to the fact that the UK composition database was used, which is not fully compatible with the Irish situation. In addition, the Irish composite dishes were highly disaggregated to their ingredients in the dataset submitted to EFSA.

Uncertainties in the estimates of all countries may be caused by inaccuracies in mapping food consumption data according to the FoodEx2 classification, analytical errors or errors in the estimation of the concentration in foods in the food composition databases, the use of borrowed phosphorus values from other countries in the food composition databases, and the replacement of missing phosphorus values by available values for similar foods or food groups in the phosphorus intake estimation process. These uncertainties may, in principle, lead to estimates of phosphorus intake that are both too high and too low. It is not possible to conclude which of these intake estimates (i.e. the EFSA intake estimate or the published one) would be closer to the actual phosphorus intake.

4. Overview of Dietary Reference Values and recommendations

4.1. Adults

The Nordic countries considered that 400 mg/day of phosphorus is adequate for adults to maintain a plasma concentration of 0.8 mmol/L. Taking into account the PRIs set by the US Institute of Medicine (IOM, 1997) and SCF (1993), and taking the view that phosphorus intakes should correspond, on a molar basis, with those of calcium, a Recommended Intake (RI) of 600 mg/day had been set earlier (Nordic Council of Ministers, 2004). For the 5th edition of the Nordic Nutrition Recommendations (NNR 2012), it was considered that there are no new data indicating that this value should be changed (Nordic Council of Ministers, 2014).

The German-speaking countries (D-A-CH, 2015) considered that data from which RIs could be derived are much rarer for phosphorus than for calcium. An AR for adults was estimated to be 580 mg/day according to the IOM (1997). Given a coefficient of variation (CV) of 10%, the RI was set at 700 mg/day.
The French Food Safety Authority (Afssa, 2001) used a factorial approach to calculate the AR. Urinary and faecal losses were estimated in accordance with Wilkinson (1976), Nordin (1989) and Lemann (1996). For absorption efficiency in adults, a mean value of 65% was used (Wilkinson, 1976; Guéguen, 1982). Using a CV of 15%, the PRI for adults was calculated to be 750 mg/day.

The IOM (1997) used the lower end of the normal adult serum inorganic phosphorus range (0.87 mmol/L) and considered that this value would be obtained by an intake of ≈ 580 mg (≈ 19 mmol)/day (Nordin, 1989), which was considered the best available Estimated Average Requirement (EAR) for adults. The extrapolation from absorbed intake to ingested intake was based on an absorption efficiency for phosphorus of 60–65% (Stanbury, 1971; Wilkinson, 1976; Heaney and Recker, 1982). A CV of 10% was used to determine a Recommended Dietary Allowance (RDA) of 700 mg (22.6 mmol)/day for adult men and women of all ages.

The SCF (1993) suggested that phosphorus intake should correspond, on a molar basis, to that for calcium, and rounded values for AR and PRI were proposed accordingly.

The Netherlands Food and Nutrition Council (1992) was unable to set a minimum requirement on the basis of the data available at that time, but estimated, for adults, that the minimum requirement was no higher than 400 mg/day (Marshall et al., 1976). However, an Adequate Range of Intake was set by relating the phosphorus requirement to the calcium requirement, which was, however, revised in the year 2000 (Health Council of the Netherlands, 2000). In 1992, in light of animal experiments (FAO/WHO, 1974; Schaafsma, 1981), it was considered that a calcium to phosphorus ratio (weight by weight) of less than 0.5:1 should be avoided. It was suggested that the lower limit of the RDA for calcium be applied as the lower limit of the Adequate Range of Intake for phosphorus. Allowing for a calcium to phosphorus ratio of 0.5:1 (weight by weight), the upper limit of the Adequate Range of Intake for phosphorus was set at twice the lower limit of the RDA for calcium. As kidney function gradually declines as ageing progresses (Rowe et al., 1976), it was stated that the regulation of phosphate balance in older adults on a phosphate-rich diet may be accompanied by chronic low-level stimulation of the parathyroid, which, in the long term, can promote bone decalcification. Therefore, the upper limit of the Adequate Range of Intake for phosphorus for adults over 50 years was calculated on the basis of a calcium to phosphorus ratio (weight by weight) of 0.7:1. The lower limit equated to that of adults up to the age of 50 years.

The UK Committee on Medical Aspects of Food Policy (COMA) (DH, 1991) took the view that requirements should be set at a ratio of 1 mmol phosphorus to 1 mmol calcium, as they are present in the body in equimolar amounts. Accordingly, the Reference Nutrient Intake (RNI) for phosphorus was set at the equimolar value of the calcium RNI.

An overview of DRVs for phosphorus for adults proposed by various committees can be found in Table 3.
Table 3: Overview of Dietary Reference Values for phosphorus for adults

<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>PRI</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Men (mg/day)</td>
<td>700</td>
<td>700</td>
<td>750</td>
<td>700</td>
<td>550</td>
<td>700–1400</td>
<td>550</td>
</tr>
<tr>
<td>Women (mg/day)</td>
<td>700</td>
<td>700</td>
<td>750 (b)</td>
<td>700</td>
<td>550</td>
<td>700–1400</td>
<td>550</td>
</tr>
<tr>
<td>Age (years)</td>
<td>≥ 19</td>
<td>18–20</td>
<td>20–64</td>
<td>≥ 19</td>
<td>≥ 18</td>
<td>19–50</td>
<td>≥ 19</td>
</tr>
<tr>
<td>PRI</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Men (mg/day)</td>
<td>600</td>
<td></td>
<td>750</td>
<td></td>
<td></td>
<td>700–1150</td>
<td></td>
</tr>
<tr>
<td>Women (mg/day)</td>
<td>600</td>
<td></td>
<td>800 (c)</td>
<td></td>
<td></td>
<td>700–1150</td>
<td></td>
</tr>
<tr>
<td>≥ 21</td>
<td>65–74</td>
<td></td>
<td>≥ 50</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Men (mg/day)</td>
<td>800</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Women (mg/day)</td>
<td>800</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

NCM, Nordic Council of Ministers; NL, Netherlands Food and Nutrition Council; PRI, Population Reference Intake.
(a): Adequate Range of Intake.
(b): 20–55 years.
(c): ≥ 55 years.
(d): Lower limit of the Adequate Range of Intake for adults below the age of 50 years is also considered adequate for this age group.

4.2. Infants and children

The Nordic countries considered that RIs for phosphorus should correspond, on a molar basis, to those for calcium (Nordic Council of Ministers, 2004). For NNR 2012, it was considered that there are no new data indicating that these values should be changed (Nordic Council of Ministers, 2014).

For puberty and adolescence, the German-speaking countries (D-A-CH, 2015) considered that the requirement for phosphorus is higher compared with that in adults because of new tissue formation and bone growth. Accordingly, an RI of 1 250 mg/day was set for children and adolescents from 10 to below 19 years of age.

Afssa (2001) proposed an Adequate Intake (AI) of 275 mg/day for infants aged 6–12 months, in line with the IOM (1997). For children, Afssa (2001) used a factorial approach to calculate the ARs. Allowing for a phosphorus content of bone (Fomon et al., 1982) and other tissues, values were derived from the amount of calcium required during growth using a calcium to phosphorus ratio of the weight gain of 1:7 up to the age of 18 years, with the amount of phosphorus required for growth ranging from 50 mg/day (age 1–3 years) to 150 mg/day (age 10–14 years). Urinary and faecal losses were estimated in accordance with Wilkinson (1976), Nordin (1989) and Lemann (1996). For absorption efficiency, mean values of 70 % (age 15–18 years) to 75 % (age 1–14 years) were used in children and adolescents (Wilkinson, 1976; Guéguen, 1982). A CV of 15 % was used to derive the PRIs.

For infants aged 0 to 6 months, the IOM (1997) set an AI of 100 mg (3.2 mmol)/day based on a mean breast milk intake of 780 mL/day (Butte et al., 1984a; Allen et al., 1991) and an average phosphorus concentration of human milk of 124 mg/L (Atkinson et al., 1995). For infants aged 6–12 months, the AI of 275 mg (8.9 mmol)/day was based on the phosphorus intake from breast milk and solid foods. An average intake of 75 mg/day was calculated from an average human milk concentration of 124 mg/L (Atkinson et al., 1995) and a mean breast milk intake of 600 mL/day (Dewey et al., 1984). The contribution from solid foods was estimated to be 200 mg/day from data on 40 infants fed standard infant formula and solid food (Specker et al., 1997), which was comparable to estimations from the 1976–1980 NHANES II for infants aged 7–12 months (Montalto and Benson, 1986). For children aged 1–3 years, an EAR of 380 mg (12.3 mmol)/day was based on a factorial estimate.9

9 EAR = (accretion + urinary loss)/fractional absorption.
Accretion of phosphorus for bone and lean tissue was estimated to be 54 mg (1.7 mmol)/day, calculated from balance studies in children aged 4–12 years (Fomon et al., 1982) corrected to the average weight gain for children aged 1–3 years. A value of 19% by weight was used as the phosphorus content of bone. The phosphorus content of lean tissue was assumed to be 0.23%, based on the known composition of muscle (Pennington, 1994). The urinary loss was calculated to be 213 mg (6.9 mmol)/day using the equation developed by Lemann (1996). A conservative estimate for efficiency of phosphorus absorption and urinary loss of phosphorus was set at a range of 1:1 to 60:1. An accretion value of 62 mg (2.0 mmol)/day was derived. The assumptions for efficiency of phosphorus absorption and urinary loss of phosphorus are identical to that used for 1-to 3-year-old children. The RDA for children aged 4–8 years was set at 500 mg (16.1 mmol)/day using a CV of 10%. As there are few balance studies in children aged 9–18 years, the same method of estimation by tissue accretion was used. Bone and lean mass accretion was estimated using three studies (Deurenberg et al., 1990; Slemenda et al., 1994; Martin et al., 1997). Assuming a phosphorus content of bone of 19% and a phosphorus content of soft tissue of 0.23% (Pennington, 1994), daily phosphorus needs during peak growth would approximate 200 mg (6.5 mmol) for boys and 150 mg (4.8 mmol) for girls. Urinary loss of phosphorus was calculated to be 565 mg (18.2 mmol)/day using the equation from Lemann (1996). Absorption efficiency was averaged to 60–80% (Lutwak et al., 1964; Greger et al., 1978) and a midpoint of 70% was used. An EAR of 1,055 mg (34 mmol)/day for both girls and boys was set; thus, with an assumed CV of 10%, the RDA was set at 1,250 mg (40.3 mmol)/day for 9- to 18-year-old children.

The SCF (1993) suggested that phosphorus intake should correspond, on a molar basis, to that for calcium and rounded PRI values were proposed accordingly.

The Netherlands Food and Nutrition Council (1992) set an Adequate Range of Intake derived from the lower limit of the Adequate Range of Intake for calcium and a recommended calcium to phosphorus ratio. For infants aged 6–12 months, a calcium to phosphorus ratio (weight by weight) of 1:1 was applied, whereas the calcium to phosphorus ratio was 0.5:1 to 1:1 (weight by weight) for children and adolescents.

The UK COMA (DH, 1991) took the view that requirements should be set at a molar calcium to phosphorus ratio of 1:1, as they are present in the body in equimolar amounts. Accordingly, the RNI for phosphorus was set at the equimolar value of the calcium RNI.

An overview of the DRVs for phosphorus for infants and children proposed by various committees can be found in Table 4.
The German-speaking countries (D-A-CH, 2015) estimated that during pregnancy an average of 60 mg/day of phosphorus must be provided to meet the needs of pregnancy. Taking into account intestinal absorption, an additional allowance of 100 mg/day was set compared with that for non-pregnant women.

Afssa (2001) used a factorial approach to estimate the AR. A full-term infant contains about 17 g of phosphorus (Fomon et al., 1982), indicating a mean retention of 150 mg/day during the last trimester of pregnancy. For absorption efficiency, mean values of 70–75 % were used for pregnant women (Wilkinson, 1976; Guéguen, 1982). An intake of 800 mg/day was recommended, taking into account inevitable bone loss and subsequent compensation.

The IOM (1997) considered that there was no evidence to support an increase in the EAR for pregnant women above that of non-pregnant women. It was noted that intestinal absorption increases by about 10 % during pregnancy (Heaney and Skillman, 1971), which was considered sufficient to provide the necessary phosphorus for fetal growth.

The Netherlands Food and Nutrition Council (1992) calculated an increased requirement of 100 mg/day during pregnancy based on the amount of phosphorus stored in the fetus.

The SCF (1993) and the UK COMA (DH, 1991) gave no increment for pregnant women compared with the DRV for non-pregnant women.

An overview of DRVs for phosphorus for pregnant women proposed by various committees can be found in Table 5.
Table 5: Overview of Dietary Reference Values for phosphorus for pregnant women

<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>PRI (mg/day)</td>
<td>1 250</td>
<td>700</td>
<td>800 (b)</td>
<td>1 250</td>
<td>550</td>
<td>800–1 600</td>
<td>550</td>
</tr>
<tr>
<td>Age (years)</td>
<td>&lt; 19</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Age (years)</td>
<td>≥ 19</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

NCM, Nordic Council of Ministers; NL, Netherlands Food and Nutrition Council; PRI, Population Reference Intake.
(a): Adequate Range of Intake.
(b): Third trimester.

4.4. Lactation

The German-speaking countries (D-A-CH, 2015) estimated that an additional amount of phosphorus of 90–120 mg/day was needed during lactation. Taking into account intestinal absorption an additional allowance of 200 mg/day was set compared to that for non-lactating women.

Afssa (2001) used the factorial approach to derive the AR for lactation. It was estimated that 120 mg/day of phosphorus is secreted via breast milk, based on an average breast milk phosphorus concentration of 150 mg/L and a daily volume of milk secretion of 800 mL. The maintenance needs during lactation were estimated at 350 mg/day and, considering an absorption efficiency of 65 % (as for non-lactating adults) (Wilkinson, 1976; Guéguen, 1982), an AR of 720 mg/day was derived. Using a CV of 15 % the PRI would have been 930 mg/day. However, Afssa selected the value of 850 mg/day to take into account the normal variation of bone stores (i.e. the obligatory loss of bone mass during pregnancy and lactation and their resturation afterwards). A PRI of 850 mg/day was also set for an equal number of months after breastfeeding to restore bone phosphorus reserves.

The IOM (1997) stated that there was no evidence to support an increase in phosphorus requirement during lactation. Apparently, increased bone resorption and decreased urinary excretion of phosphorus (Kent et al., 1990), which occur independently of dietary intake of phosphorus or calcium, provide the necessary phosphorus for milk production. Therefore, the EAR and RDA were estimated to be similar to those set for non-lactating women of the respective age groups.

The SCF (1993) suggested that phosphorus intake should correspond, on a molar basis, to that for calcium and a rounded PRI value was proposed accordingly.

The Netherlands Food and Nutrition Council (1992) assumed an increased phosphorus need of 200 mg/day, calculated on the basis of the phosphorus concentration in breast milk and an absorption efficiency of 60 % (Spencer et al., 1984).

The UK COMA (DH, 1991) took the view that requirements should be set at a ratio of 1 mmol phosphorus to 1 mmol calcium, as they are present in the body in equimolar amounts. Accordingly, the RNI for phosphorus was set at the equimolar value of the calcium RNI.

An overview of DRVs for phosphorus for lactating women proposed by various committees can be found in Table 6.
Table 6: Overview of Dietary Reference Values for phosphorus for lactating women

<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Age (years)</td>
<td>&lt; 19</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>14–18</td>
<td></td>
</tr>
<tr>
<td>PRI (mg/day)</td>
<td>1 250</td>
<td>900</td>
<td>850</td>
<td>1 250</td>
<td>950</td>
<td>900–1 800</td>
<td>+ 440</td>
</tr>
<tr>
<td>Age (years)</td>
<td>≥ 19</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>19–50</td>
<td></td>
</tr>
<tr>
<td>PRI (mg/day)</td>
<td>900</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>700</td>
<td></td>
</tr>
</tbody>
</table>

(a): Adequate Range of Intake.

NCM, Nordic Council of Ministers; NL, Netherlands Food and Nutrition Council; PRI, Population Reference Intake.

5. Criteria (endpoints) on which to base Dietary Reference Values

5.1. Indicators of phosphorus requirement

As stated in Section 2.4, the Panel considers that there is no suitable biomarker of phosphorus intake or status that can be used for setting DRVs for phosphorus.

5.2. Balance studies on phosphorus

Balance studies are based on the assumption that a healthy subject on an adequate diet maintains an equilibrium or a null balance between nutrient intakes and nutrient losses: at this null balance, the intake matches the requirement determined by the given physiological state of the individual. When intakes exceed losses (positive balance), there is nutrient accretion that may be attributable to growth or to weight gain, anabolism or repletion of stores; when losses exceed intakes (negative balance), nutrient stores are progressively depleted resulting, in the long term, in clinical symptoms of deficiency. In addition to numerous methodological concerns about accuracy and precision in the determination of intakes and losses (Baer et al., 1999), the validity of balance studies for addressing requirements has been questioned: they might possibly reflect only adaptive changes before a new steady state is reached (Young, 1986), or they might reflect only the conditions for maintenance of nutrient stores and exchangeable body pools in the context of a given diet, and the relevance for health of the size of the pools still needs to be established for each nutrient (Mertz, 1987).

Few phosphorus balance studies are available in comparison with studies on other minerals, such as calcium, partly because phosphorus isotopes cannot be safely used for kinetic studies. Thus, the study of the regulation of phosphorus homeostasis has often been considered as subordinate to that of calcium. Phosphorus balance, like calcium balance, is maintained by intestinal absorption, renal excretion and bone accretion. However, there are important differences between phosphorus and calcium balance. Dietary phosphorus, which grossly parallels dietary protein, is present in abundance in most foods; this is in contrast to calcium, which is restricted to relatively few food groups. Dietary phosphorus is absorbed more efficiently than dietary calcium. Thus, phosphorus absorption is not a limiting factor, whilst renal elimination may be a limiting factor at intakes that result in a filtered glomerular load exceeding the renal tubular reabsorption capacity.

5.2.1. Balance studies in adults

Roberts et al. (1948) evaluated phosphorus losses and retention in nine healthy postmenopausal women (age 52–74 years). After 3–5 weeks on a habitual diet with replicated menus, phosphorus balance was evaluated in two consecutive 5-day balance periods. Mean phosphorus intake on self-selected diets was 1 100 mg/day (range 891–1 403 mg/day). At an intake below 1 100 mg/day, all balances were negative, between 1 100 and 1 400 mg/day no consistent trend was observed, while at a phosphorus intake above 1 400 mg/day, positive balances were more frequent than negative balances. However, the authors concluded that in this study the variation in individual responses to a given phosphorus intake was so high that phosphorus requirements could not be determined with validity, even at the individual level.
Ohlson et al. (1952) evaluated phosphorus balance in a multicentre study in 136 women (30–85 years of age) on self-selected diets. No standardisation of the pre-balance period was performed. Phosphorus intake was highly variable, ranging from 490 to 1700 mg/day, with a significant decrease of phosphorus intake with increasing age. Phosphorus balance was evaluated in one balance period (from 7 to 10 days). The prediction of phosphorus intake required for zero balance (using a linear regression equation) was 1250 mg/day from 30 to 39 years of age, 1320 mg/day from 40 to 49 years, 1420 mg/day from 50 to 59 years, 1510 mg/day from 60 to 69 years and 1130 mg/day from 70 to 79 years. The Panel notes that in this multicentre study a considerable degree of uncertainty exists with regard to study procedures, selection of the participants and standardisation of dietary intake.

Scouler et al. (1957) undertook a long-term balance study in 125 young women (17–27 years of age) on self-selected diets with a day-to-day variation in phosphorus intake ranging from 120 to 400 % of the daily intake suggested by the US National Research Council (NRC, 1953). Phosphorus intake was related to balance being positive or negative, but absolute values for balances were not given. The average total intake of phosphorus associated with a positive balance was 1150 mg/day.

Marshall et al. (1976) reported on balance studies that aimed to evaluate calcium, magnesium and phosphorus requirements in adults. Participants were administered a constant diet for two weeks. Phosphorus intake ranged from about 400 mg/day to 3800 mg/day. Faeces and urine were collected from days 8 to 14. The final balance was the mean of the daily balances in the second week. Based on 646 balances, phosphorus balance was zero down to a phosphorus intake of 400 mg/day. The authors concluded that it is not possible to define phosphorus requirements based on these data.

In a balance study that aimed to evaluate the effect of phosphorus on the intestinal absorption of calcium (Spencer et al., 1978), 19 male subjects (average age 54 years, range 38–65 years) received, under metabolic ward conditions, up to five different levels of dietary calcium (from 200 to 2700 mg/day) at up to two different levels of dietary phosphorus (800 mg/day and 2000 mg/day). The diet was kept constant for several weeks or months prior to the start of the balance studies and throughout the study phases, and was analysed for nitrogen, calcium and phosphorus in each metabolic period. The minimum duration of each study period was 22 days and the duration of balance periods was 6 days. Phosphorus balance was positive or zero at each level of phosphorus and calcium intake.

Spencer et al. (1984) studied the effect of calcium on phosphorus metabolism in adult males by determining phosphorus and calcium balances during three different levels of calcium intake of approximately 200, 800 and 2000 mg/day. Each of these calcium intakes was given with two different intake levels of phosphorus of approximately 800 and 2000 mg/day to 44 adult male subjects (aged 31–71 years). Participants had received a standard diet and a constant daily fluid intake under metabolic ward conditions for a minimum of three weeks before the start of the balance studies. In each metabolic period, aliquots of the diet were analysed. Negative phosphorus balance (~60 mg/day) was observed during only the “low” calcium (200 mg/day) and the “normal” phosphorus (800 mg/day) diet period. Under all other dietary conditions, phosphorus balance was zero or positive. In particular, under conditions of “normal” calcium and phosphorus intake (defined as 800 mg/day), a slightly positive phosphorus balance was observed.

Mahalko et al. (1983) evaluated mineral utilisation by metabolic balance techniques in 10 healthy male volunteers fed diets containing 65 and 94 g protein/day. Both diets contained approximately 1000 mg phosphorus/day. Mineral balances were measured on the final 12 days of each 28-day diet period and duplicate samples of the diet were analysed. A phosphorus balance of zero was observed at both levels of protein intake.

Lakshmanan et al. (1984) assessed calcium and phosphorus balances in 13 men aged 22–49 years and in 16 women aged 20–53 years over a 1-year period, in which subjects consumed self-selected diets. An additional three men and two women participated in the study for one- to three-quarters of the year. Once every season, the subjects collected duplicate food and beverage samples for one week; the phosphorus content of the diet was analysed, as was the phosphorus concentration in faeces and urine.
collected during the week. Although the average daily intake of phosphorus was considered “adequate” (1 533 mg/day in men and 1 059 mg/day in women), the authors reported an unexpectedly high percentage (75 %) and extent of negative phosphorus balances (mean of all women: −130 mg/day; mean of all men: −239 mg/day) in these subjects consuming self-selected diets. The Panel considers that no conclusions can be drawn from this study because of the absence of an equilibration period with a standardised diet and metabolic ward conditions.

Spencer et al. (1994) evaluated balances of calcium, magnesium and phosphorus in five healthy males at two different intake levels of calcium (240 and 800 mg/day) and magnesium (about 250 and 800 mg/day). Dietary phosphorus was about 800 mg/day (range of means in four studies 765–858 mg/day). After an equilibration period of four weeks, 6-day balance studies were performed under metabolic ward conditions. Phosphorus balances were positive (means from +16 to +38 mg/day) under all different dietary conditions.

Nishimuta et al. (2004) aimed to estimate the requirements for calcium, magnesium and phosphorus in Japanese adults. A total of 109 volunteers (23 males, 86 females), ranging from 18 to 28 years of age, took part in mineral balance studies; the duration of these studies ranged from 5 to 12 days, with 2 to 4 days of adaptation. Dietary menus were designed so as to meet dietary allowances in Japan. Dietary phosphorus intake (from duplicate diet analysis) ranged from 13.5 to 45.7 mg/kg body weight per day. No absolute balance data were reported. The mean value and upper limit of the 95 % confidence interval (CI) of the dietary intake of phosphorus when the balance of phosphorus was equal to zero were 22.6 and 24.1 mg/kg body weight per day, respectively. The Panel notes the short equilibration period in this study.

Nishimuta et al. (2012) evaluated the estimated equilibrated dietary intake, defined as the intercept of a linear regression equation between intake (Y) and balance (X), for nine essential minerals including phosphorus, using data from 13 studies in young women (n = 131, range 18–26 years) consuming a standard diet designed to meet dietary allowances in Japan. Before the balance period, a 2- to 4-day adaptation period took place, during which participants were given the experimental diets. Duplicate diet samples were obtained and analysed. Mean and median phosphorus balances were close to zero (mean −0.18 ± 1.45 mg/kg body weight per day; median −0.21 mg/kg body weight per day). The estimated equilibrated dietary intake for phosphorus was 17.2 mg/kg standard body weight10 per day (95 % CI 16.7–17.8 mg/kg standard body weight per day). This value was superimposable to the estimated dietary intake of phosphorus during the balance study (17.2 ± 3.1 mg/kg standard body weight per day). The Panel notes the short equilibration period in this study.

The Panel notes that the available phosphorus balance studies are rather heterogeneous with regard to the population examined, the presence and duration of equilibration periods, the duration of balance periods, the level of phosphorus intake and the intake of calcium and other dietary factors possibly affecting phosphorus metabolism, that only a few studies were conducted under metabolic ward conditions and that zero phosphorus balance may be achieved across a wide range of intakes and across a wide range of dietary molar calcium to phosphorus ratios. The Panel notes the many limitations of these studies and considers that balance studies cannot be used for setting DRVs for phosphorus for adults.

5.2.2. Balance studies in children

Greger et al. (1978) assessed calcium, magnesium, phosphorus, copper and manganese balances in 14 girls (aged 12.5–14.5 years) during a 30-day period at two different levels of dietary zinc (7.4 or 13.4 mg/day) and after a 9-day equilibration period. Dietary phosphorus intake was set at 850 mg/day (data from analysed diets). At this intake level, the participants were in slightly positive phosphorus balance.

10 Body weight based on height and a body mass index of 22 kg/m².
The Panel notes that the data available are from only one small study in female adolescents and considers that balance studies cannot be used for setting DRVs for phosphorus for children.

5.2.3. Balance studies in pregnancy

Ashe et al. (1979) evaluated the retention of calcium, iron, phosphorus and magnesium in 10 healthy pregnant white women consuming self-selected diets. Between weeks 5 and 36 of gestation, a maximum of six 7-day balance periods were completed on each subject. Average calcium intake was 1 370 ± 290 mg/day. At an estimated phosphorus intake of 1 340 ± 280 mg/day, zero phosphorus balance was observed. The Panel notes that in this study under free-living conditions a very large intra- and inter-subject variation from one 7-day experimental period to another was observed.

The Panel considers that balance studies cannot be used for setting DRVs for phosphorus for pregnant women.

5.3. Phosphorus requirements in pregnancy and lactation

The role of dietary phosphorus during pregnancy and lactation has not been established. The Panel notes that no quantitative assessment of phosphorus resorption from bone during lactation is available. However, extended lactation is associated with a modest reduction in BMD, with a return to baseline values 12 months after parturition (Sowers et al., 1993; Karlsson et al., 2001) independently of the length of lactation (Moller et al., 2012).

Prentice (2003) reviewed the evidence regarding biological adaptation mechanisms (increases in food intake, elevated gastro-intestinal absorption, decreased mineral excretion and mobilisation of tissue stores) required to preserve the maternal mineral economy while meeting the additional mineral requirements during pregnancy and lactation. The author concluded that pregnancy and lactation are associated with physiological adaptive changes in mineral metabolism that are independent of maternal mineral supply within the range of normal dietary intakes. These processes provide the minerals necessary for fetal growth and breast milk production without requiring an increase in maternal dietary intake or compromising maternal bone health in the long term.

5.4. Phosphorus intake and health consequences

A comprehensive search of the literature published between 1990 and September 2012 was performed as preparatory work to the present Opinion, to identify relevant health outcomes upon which DRVs for phosphorus may potentially be based (Eeuwijk et al., 2012). This literature search has been updated to cover the time from September 2012 to December 2014. The relationship between phosphorus intake and various health outcomes has been investigated in a number of observational studies, while intervention studies with phosphorus as a single nutrient are not available. In the absence of reliable biomarkers of phosphorus intake and status (Section 2.4), only studies relating phosphorus intake to health outcomes will be considered for this section, though the Panel notes the difficulty in assessing phosphorus intake as a result of inaccuracies in food composition tables (Section 3.1) and variations in phosphorus absorption due to nutrient interactions (see Sections 2.3.1 and 2.3.7).

5.4.1. Bone health

Prospective studies report on the association between phosphorus intake and bone health in children. In three studies, maternal phosphorus intake during pregnancy and the bone mass of the child were studied. In one study, diet and lifestyle factors in children in relation to their bone mass were studied.

Jones et al. (2000) and Yin et al. (2010) reported on the association between maternal phosphorus intake and bone mass in children in the same prospective cohort study in Tasmania, Australia. Jones et al. (2000) investigated bone mass in children aged 8 years. Yin et al. (2010) investigated bone mass in the same population at 16 years of age. Maternal dietary intake during the third trimester of pregnancy was measured using a self-administered FFQ. Phosphorus density of the maternal diet (mg/kcal or MJ) was calculated by dividing estimated daily phosphorus intake by the estimated total daily energy.
intake. At ages 8 and 16 years, dual-energy X-ray absorptiometry (DXA) was performed. As not all children in the cohort underwent a scan at both 8 and 16 years of age, the populations described in the studies of Jones et al. (n = 173) and Yin et al. (n = 216) are not identical. Mean maternal phosphorus intake during the third trimester of pregnancy was 2.767 ± 1.655 mg/day (Jones et al., 2000) and 2.314 ± 0.898 mg/day (Yin et al., 2010). At age 8 years, the BMD of the femoral neck and lumbar spine were positively associated (p = 0.01 and p = 0.001) with the phosphorus density of the maternal diet. Total body BMD was not associated with phosphorus density of the maternal diet (p = 0.054). At age 16 years, none of the BMD measures were associated with maternal phosphorus intake. In both studies, regression models were adjusted for children’s current calcium intake. The Panel notes that the children who took part in this study were originally selected on the basis of having a higher risk of sudden infant death syndrome, that adjustments for multiple comparisons were not performed and that the self-reported maternal intake of protein, calcium, magnesium and phosphorus was very high, and much higher than in Australian pregnant women (Hure et al., 2009) and than Australian recommended intakes (NHMRC, 2005).

Tobias et al. (2005) studied the relationship between maternal diet during pregnancy, evaluated by an FFQ, and bone mass in childhood in the Avon Longitudinal Study of Parents and Children (ALSPAC) cohort in the UK. Data from 4,451 mother–child pairs were analysed. Mean maternal phosphorus intake during pregnancy was 1.339 ± 0.338 mg/day, which is comparable to the mean daily intake of 1.112 ± 0.299 mg/day measured in women in the UK (Henderson et al., 2003). Bone mineral mass of the children was measured at 9 years of age. At multivariate analysis, including other maternal dietary factors, intake of phosphorus during pregnancy was not associated with measures of bone density in children (p = 0.128). Analyses were not adjusted for children’s intakes of calcium or other micro- or macronutrients.

Bounds et al. (2005) evaluated the association between diet and lifestyle factors and bone mineral indices in a cohort of 52 children. During 8 years of follow-up, dietary data and data on sedentary activities (i.e. time not spent in physical activity) of the children were collected. Dietary intake was assessed at nine collection points (from 2.3 to 8 years of age) by means of in-home dietary interviews. Bone mineral indices were measured by DXA when children were 8 years old. Correlations between phosphorus intake and bone mineral content (BMC) (r = 0.33) and BMD (r = 0.30) were significant (p < 0.05). In a multivariate regression model predicting BMC at 8 years of age, phosphorus intake showed a small but significant contribution to the model (β = 0.11; R² = 0.05; p = 0.01). However, calcium and other micro- or macronutrients were not included in the regression model.

The Panel notes that there is some indication that maternal intake of phosphorus during pregnancy may be associated with the BMD of the femoral neck and lumbar spine, but not total body BMD in the offspring at age 8 years and that phosphorus intake during childhood may be associated with BMD at the age of 8 years. The Panel notes, however, the many limitations of these studies.

The Panel considers that measures of bone health cannot be used to derive DRVs for phosphorus during pregnancy and in children.

5.4.1.1. Dietary calcium to phosphorus ratio in relation to bone health

Several committees have set DRVs for phosphorus corresponding to those for calcium, either on a molar basis or on a weight basis. The importance of the molar ratio of calcium to phosphorus during growth has been acknowledged (EFSA NDA Panel, 2014). In adults, there are findings that suggest that the ratio of these two minerals in the diet may have a greater influence than the absolute intake of phosphorus. Animal studies (in rats, dogs, baboons and other species) have shown that high phosphorus intake in combination with low calcium intake may contribute to secondary hyperparathyroidism, bone resorption, low peak bone mass and increased bone fragility (reviewed in Calvo and Tucker (2013)). Cross-sectional studies suggest that the dietary calcium to phosphorus molar ratio is significantly associated with (site-specific) BMD and/or BMC (Teegarden et al., 1998; Brot et al., 1999; Ito et al., 2011) or indicators of bone metabolism (Kemi et al., 2008; Kemi et al.,
2010). In some studies, the dietary calcium to phosphorus molar ratio was more closely related to both BMD and indicators of bone metabolism than the calcium or phosphorus intake per se. A mild phosphorus-induced secondary hyperparathyroidism could be considered a plausible mechanism for the association between a low dietary calcium to phosphorus molar ratio and lower BMD or BMC. The Panel notes, however, that other studies present conflicting evidence (Heaney and Recker, 1987; Heaney and Nordin, 2002).

Thus, the Panel considers that the data cannot be used to define a precise dietary calcium to phosphorus molar ratio in adults for bone health, but notes that calcium and phosphorus are present in bone in a molar ratio of approximately 1.6:1 to 1.8:1 (Section 2.3.3.1).

5.4.2. Cancer

Few prospective studies have evaluated the association between dietary phosphorus intake and some types of cancer. The World Cancer Research Fund included phosphorus among the exposures for which data were either of too low quality, too inconsistent, or the number of studies too few to allow conclusions to be reached on an association with cancer (WCRF/AICR, 2007).

5.4.2.1. Prostate cancer

Chan et al. (2000) prospectively evaluated the association between dietary phosphorus intake, assessed by self-administered FFQ, and prostate cancer in 27 062 Finnish male smokers included in the Alpha-Tocopherol Beta-Carotene Cancer Prevention (ATBC) Study. No significant independent associations of phosphorus and calcium intake with prostate cancer risk were observed. Men with lower calcium and higher phosphorus intake had a multivariate relative risk (RR) of 0.6 (95 % CI = 0.3–1.0) compared with men with lower intakes of both nutrients, after adjustment for age, smoking, body mass index, total energy intake, education and supplementation group, thus suggesting a possible interaction between the two nutrients.

Kesse et al. (2006) prospectively evaluated the association between dietary phosphorus intake, measured by at least five 24-hour records in the first 18 months of the study, and prostate cancer in 2 776 men in the SU.VI.MAX trial (SUplémentation en VItamines et Minéraux Anti-oXydants). In almost 8 years of follow-up, 69 incident cases of prostate cancer occurred in the study population. A weak positive association between phosphorus intake and prostate cancer was observed (p_trend = 0.04), with a non-significant RR of 1.83 (95 % CI = 0.89–3.73) comparing the highest versus the lowest quartile.

Tseng et al. (2005) prospectively evaluated the association between dietary phosphorus intake and prostate cancer in 3 612 men from the National Health and Nutrition Examination Epidemiologic Follow-up Study. Dietary intake was assessed by FFQ. After almost 8 years of follow-up, there were 131 new cases of prostate cancer in the population. No association between phosphorus intake and prostate cancer risk was found in the fully adjusted regression model including calcium intake (RR for the highest tertile of phosphorus intake compared with the lowest tertile was 0.9, 95 % CI = 0.5–1.6, p_trend = 0.77).

5.4.2.2. Other types of cancer

Michaud et al. (2000) examined the relationship between intakes of macro- and micronutrients and the risk of bladder cancer among men in the prospective Health Professionals Follow-Up Study. Dietary intake was assessed by FFQ. During 12 years of follow-up, 320 cases of bladder cancer were diagnosed in a population of 47 909 men. Phosphorus intake was not associated with the incidence of bladder cancer (p_trend = 0.40). The multivariate adjusted RR (not adjusted for calcium) of the highest quintile (median phosphorus intake 1 728 mg/day) compared with the lowest quintile (median phosphorus intake 1 101 mg/day) was 0.85 (95 % CI = 0.57–1.21).

Kesse et al. (2005) investigated the association between phosphorus intake and risk of colorectal adenoma and cancer among women in the French component of the European Prospective
Investigation into Cancer and Nutrition (E3N-EPIC) prospective study. Dietary data were collected using an FFQ. After 3.7 years of follow-up, 516 women were diagnosed with adenomas and 4,804 women were free of polyps, being confirmed by colonoscopy. For the colorectal cancer study, after a follow-up of 6.9 years, 172 cases of colorectal cancer were identified, while 67,312 women were free of the disease. A higher phosphorus intake was associated with a decreased risk of adenomas ($P_{	ext{trend}} = 0.005$). The RR of the highest quartile (median phosphorus intake > 1,634 mg/day) compared with the lowest quartile (median < 1,412 mg/day) of intake was 0.70 (95% CI = 0.54–0.90). In a sub-group of women with high-risk adenomas, no association was observed. This sub-group (n = 175) covered women diagnosed with large adenomas (≥ 1 cm in diameter), adenomas with severe dysplasia and multiple adenomas (three or more), and those with a villous component. No significant association between phosphorus intake and colorectal cancer was found.

5.4.2.3. Conclusions on cancer-related outcomes

The Panel considers that evidence of an association between phosphorus intake and cancer-related outcomes is inconsistent, and that available data on such outcomes cannot be used as criteria for deriving DRVs for phosphorus.

5.4.3. Cardiovascular disease-related outcomes and all-cause mortality

Some observational studies are available that evaluated the association between phosphorus intake and cardiovascular disease (CVD).

Chang et al. (2014) prospectively investigated the association between phosphorus intake and mortality in 9,686 adults aged 20–80 years without diabetes, cancer, kidney diseases or CVD participating in NHANES III (1988–1994). Dietary phosphorus intake, assessed by 24-hour dietary recall, was expressed as the absolute intake and as phosphorus density (phosphorus intake divided by energy intake). Median follow-up time was 14.7 years. In analyses adjusted for demographics, cardiovascular risk factors, kidney function and energy intake (not adjusted for calcium intake), higher phosphorus intake was associated with higher all-cause mortality in individuals who consumed > 1,400 mg/day (adjusted hazard ratio (HR) = 2.23, 95% CI = 1.09–4.5, per 1-unit increase in log-transformed phosphorus intake, p = 0.03). At < 1,400 mg/day, there was no association. A similar association was seen between higher phosphorus density and all-cause mortality at a phosphorus density > 0.35 mg/kcal (adjusted HR = 2.27, 95% CI = 1.19–4.33, per 0.1 mg/kcal-increase in phosphorus density, p = 0.01). Phosphorus density was associated with cardiovascular mortality (adjusted HR = 3.39, 95% CI = 1.43–8.02, per 0.1 mg/kcal at > 0.35 mg/kcal, p = 0.01), whereas no association was shown in analyses with phosphorus intake. The Panel notes that only a single measurement, as a 24-hour dietary recall, was used to assess phosphorus intake. Moreover, the nutrient database used in this study was unable to differentiate between organic and inorganic sources of phosphorus (Anonymous, 1994).

5.4.3.1. Left ventricular mass

Yamamoto et al. (2013) investigated the association between dietary phosphorus intake and left ventricular mass in 4,494 participants from the Multi-Ethnic Study of Atherosclerosis, a community-based study of individuals free of known CVD. The intake of dietary phosphorus was estimated using a 120-item FFQ and left ventricular mass was measured using magnetic resonance imaging. In the fully adjusted model, each 20% increase in estimated dietary phosphorus intake was associated with an increase in left ventricular mass of 1.06 g (95% CI = 0.50–1.62, p < 0.001). The Panel notes the many limitations of this study, including its cross-sectional design.

5.4.3.2. Hypertension

Alonso et al. (2010) analysed the associations of dietary phosphorus (assessed by validated FFQ) with blood pressure at the baseline visit and incidence of hypertension in 13,444 participants from the Atherosclerosis Risk in Communities and the Multi-Ethnic Study of Atherosclerosis cohorts. They found that, compared with individuals in the lowest quintile of phosphorus intake, those in the highest
quintile had lower systolic and diastolic blood pressures after adjustment for potential confounders. Furthermore, higher dietary phosphorus intake was associated with a lower risk of developing future hypertension after adjustment for non-dietary confounders (HR = 0.80, 95 % CI = 0.80–1.00, comparing extreme quintiles, p_trend = 0.02); however, this association was no longer significant after adjustment for dietary factors (HR = 1.01, 95 % CI = 0.82–1.23, p_trend = 0.88). After adjustment, phosphorus only from dairy products, but not from other sources, was associated with lower baseline blood pressure and reduced risk of incident hypertension. HRs (95 % CIs) comparing extreme quintiles were 0.86 (95 % CI = 0.76–0.97, p_trend = 0.01) for phosphorus from dairy foods and 1.04 (95 % CI = 0.93–1.17, p_trend = 0.48) for phosphorus from other foods. The Panel notes the high correlation of phosphorus with other nutrients potentially associated with blood pressure, such as calcium, magnesium and potassium, and that the potential benefits seem to be restricted to phosphorus obtained through the intake of dairy products. This finding could be indicative of an effect of phosphorus in conjunction with other dairy constituents or of dairy foods themselves, even without an involvement of phosphorus.

5.4.3.3. Conclusions on cardiovascular disease-related outcomes and all-cause mortality

The Panel considers that evidence related to all-cause mortality and cardiovascular outcomes, including blood pressure, is limited and inconsistent and cannot be used to derive DRVs for phosphorus.

6. Data on which to base Dietary Reference Values

6.1. Adults, infants aged 7–11 months and children

The Panel considers that there are currently no reliable biomarkers of phosphorus intake and status that may be used for deriving the requirement for phosphorus (Section 2.4). In addition, the Panel notes that estimations of phosphorus absorption from the diet (Section 2.3.1), as well as losses of phosphorus via urine (Section 2.3.6.1) and faeces (Section 2.3.6.2), vary over a wide range, so that the factorial approach cannot be used for deriving the requirement for phosphorus. The Panel also considers that data on balance studies and on phosphorus intake and health outcomes cannot be used for setting DRVs for phosphorus.

Instead, the Panel proposes to use the calcium to phosphorus ratio in the whole body to set DRVs for phosphorus, taking into account the DRVs for calcium (EFSA NDA Panel, 2015). The Panel notes that data on the molar ratio of calcium to phosphorus in the intact bone of healthy adults, used for extrapolation of the whole-body calcium to phosphorus ratio (Section 2.3.3.1), and data from whole-body calcium and phosphorus measurements in Caucasian men and women (Section 2.3.3.1) indicate that the calcium to phosphorus molar ratio in the whole body ranges from 1.4:1 to 1.9:1.

In adults, the data on net phosphorus absorption have been reported to vary over a wide range (Section 2.3.1). The Panel notes that the fractional absorption of phosphorus is higher than that of calcium (EFSA NDA Panel, 2015), but the Panel considers that the actual amounts of calcium and phosphorus that are available for absorption from the diet and may be retained in the body cannot be determined. In the absence of this information, the Panel proposes to set DRVs for phosphorus based solely on the range of the molar ratio of calcium to phosphorus in the body.

The Panel considers that the available data are insufficient to derive ARs and PRIs for phosphorus, and therefore the Panel proposes to set AIs for all population groups. Based on the AI (for infants aged 7–11 months) and the PRIs (for all other ages) for calcium (EFSA NDA Panel, 2015), and considering a molar calcium to phosphorus ratio of 1.4:1 to 1.9:1, amounts of phosphorus (in mg/day) were calculated (Appendix F). The Panel chose the lower bound of this range (i.e. a ratio of 1.4:1 which results in the higher phosphorus intake value) for deriving an AI for phosphorus, taking into account estimated phosphorus intakes in Western countries, which are considerably higher (Section 3.2) than the values calculated in Appendix F. AIs for all age groups were set after rounding to the nearest
10 mg/day (Table 7). The Panel considers that the AIs proposed for infants and children cover the quantity of phosphorus estimated for accretion in bone in these age groups (Section 2.3.4).

6.2. Pregnancy and lactation

The Panel acknowledges the existence of physiological adaptive processes that ensure sufficient phosphorus for fetal growth and breast milk production. These may obviate the need for additional dietary phosphorus during pregnancy and lactation, provided intake is close to the AI for adults (see Section 5.3). Therefore, the Panel concludes that additional dietary phosphorus is not required for pregnant and lactating women.

CONCLUSIONS

The Panel derived DRVs for phosphorus based on the AI (for infants aged 7–11 months) and the PRIs (for all other age groups) for calcium. The Panel used data on the calcium to phosphorus ratio in the bone of healthy men and women and adjusted these data for the proportion of phosphorus present outside bone. In addition, data on whole-body contents of calcium and phosphorus in Caucasian adults were used to calculate molar calcium to phosphorus ratios in the whole body. These data indicate that the calcium to phosphorus molar ratio in the whole body ranges from 1.4:1 to 1.9:1. The Panel considered that the available data are insufficient to derive ARs and PRIs for phosphorus and, therefore, the Panel proposed that AIs are set for all population groups. For this, the Panel chose the lower bound of the range (i.e. a calcium to phosphorus molar ratio in the whole body of 1.4:1, which results in the higher phosphorus intake value) for setting an AI for phosphorus (Table 7), taking into account estimated phosphorus intakes in Western countries, which are considerably higher than the values calculated on the basis of this range. It was considered that the AI for adults should also apply to pregnant and lactating women.

Table 7: Summary of Adequate Intakes for phosphorus

<table>
<thead>
<tr>
<th>Age</th>
<th>Adequate Intake (mg/day)</th>
</tr>
</thead>
<tbody>
<tr>
<td>7–11 months</td>
<td>160</td>
</tr>
<tr>
<td>1–3 years</td>
<td>250</td>
</tr>
<tr>
<td>4–10 years</td>
<td>440</td>
</tr>
<tr>
<td>11–17 years</td>
<td>640</td>
</tr>
<tr>
<td>Adults ≥ 18 years (a)</td>
<td>550</td>
</tr>
</tbody>
</table>

(a): Including pregnant and lactating women.

RECOMMENDATIONS FOR RESEARCH

The Panel recommends that studies be undertaken to better characterise biomarkers of phosphorus status, including phosphatonin and especially FGF-23.

The Panel recommends that research be undertaken on the effect of dietary phosphorus intake on long-term health outcomes and the risk of chronic disease.

The Panel recommends that dietary assessment tools be developed, allowing for the quantification of phosphorus-based additives used in food processing and in some carbonated beverages.
REFERENCES


Eto N, Tomita M and Hayashi M, 2006. NaPi-mediated transcellular permeation is the dominant route in intestinal inorganic phosphate absorption in rats. Drug Metabolism and Pharmacokinetics, 21, 217-221.
Dietary Reference Values for phosphorus


Dietary Reference Values for phosphorus


# APPENDICES

Appendix A. Dietary surveys in the EFSA Comprehensive European Food Consumption Database included in the nutrient intake calculation and number of subjects in the different age classes

<table>
<thead>
<tr>
<th>Country</th>
<th>Dietary survey</th>
<th>Year</th>
<th>Method</th>
<th>Days</th>
<th>Age (years)</th>
<th>Infants &lt; 1 year</th>
<th>Children 1–&lt; 3 years</th>
<th>Children 3–&lt; 10 years</th>
<th>Children 10–&lt; 18 years</th>
<th>Adults 18–&lt; 65 years</th>
<th>Adults 65–&lt; 75 years</th>
<th>Adults ≥ 75 years</th>
</tr>
</thead>
<tbody>
<tr>
<td>Finland/1</td>
<td>DIPP</td>
<td>2000–2010</td>
<td>Dietary record</td>
<td>3</td>
<td>&lt; 1–6</td>
<td>499</td>
<td>500</td>
<td>750</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Finland/2</td>
<td>NWSSP</td>
<td>2007–2008</td>
<td>48-hour dietary recall (a)</td>
<td>2 x 2 (a)</td>
<td>13–15</td>
<td>306</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Finland/3</td>
<td>FINDIET2012</td>
<td>2012</td>
<td>48-hour dietary recall (a)</td>
<td>2</td>
<td>25–74</td>
<td>1 295</td>
<td>413</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>France</td>
<td>INCA2</td>
<td>2006–2007</td>
<td>Dietary record</td>
<td>7</td>
<td>3–79</td>
<td>482</td>
<td>973</td>
<td>2 276</td>
<td>264</td>
<td>84</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Germany/1</td>
<td>EsKiMo</td>
<td>2006</td>
<td>Dietary record</td>
<td>3</td>
<td>6–11</td>
<td>835</td>
<td>393</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Germany/2</td>
<td>VELS</td>
<td>2001–2002</td>
<td>Dietary record</td>
<td>6</td>
<td>&lt; 1–4</td>
<td>158</td>
<td>347</td>
<td>299</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Ireland</td>
<td>NANS</td>
<td>2008–2010</td>
<td>Dietary record</td>
<td>4</td>
<td>18–90</td>
<td></td>
<td></td>
<td></td>
<td>1 274</td>
<td>149</td>
<td>77</td>
<td></td>
</tr>
<tr>
<td>Italy</td>
<td>INRAN-SCAI 2005–06</td>
<td>2005–2006</td>
<td>Dietary record</td>
<td>3</td>
<td>&lt; 1–98</td>
<td>16 (b)</td>
<td>36 (b)</td>
<td>193</td>
<td>247</td>
<td>2 313</td>
<td>290</td>
<td>228</td>
</tr>
<tr>
<td>Latvia</td>
<td>FC_PREGNANTWOMEN</td>
<td>2011</td>
<td>24-hour dietary recall</td>
<td>2</td>
<td>15–45</td>
<td></td>
<td></td>
<td></td>
<td>12 (b)</td>
<td>991 (b)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Netherlands</td>
<td>DNFSC</td>
<td>2007–2010</td>
<td>24-hour dietary recall</td>
<td>2</td>
<td>7–69</td>
<td>447</td>
<td>1 142</td>
<td>2 057</td>
<td>173</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Sweden</td>
<td>RISKMATEN</td>
<td>2010–2011</td>
<td>Dietary record (web) (d)</td>
<td>4</td>
<td>18–80</td>
<td></td>
<td></td>
<td></td>
<td>1 430</td>
<td>295</td>
<td>72</td>
<td></td>
</tr>
<tr>
<td>UK/1</td>
<td>DNSIYC-2011</td>
<td>2011</td>
<td>Dietary record</td>
<td>4</td>
<td>0.3–1.5</td>
<td>1 369</td>
<td>1 314</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>UK/2</td>
<td>NDNS Rolling Programme</td>
<td>2008–2011</td>
<td>Dietary record</td>
<td>4</td>
<td>1–94</td>
<td>185</td>
<td>651</td>
<td>666</td>
<td>1 266</td>
<td>166</td>
<td>139</td>
<td></td>
</tr>
</tbody>
</table>

DIPP, Type 1 Diabetes Prediction and Prevention survey; DNFCs, Dutch National Food Consumption Survey; DNSIYC, Diet and Nutrition Survey of Infants and Young Children; EsKiMo, Ernährungsstudie als KIGGS-Modul; FINDIET, the national dietary survey of Finland; INCA, Étude Individuelle Nationale des Consommations Alimentaires; INRAN-SCAI, Istituto Nazionale di Ricerca per gli Alimenti e la Nutrizione – Studio sui Consumi Alimentari in Italia; FC_PREGNANTWOMEN, food consumption of pregnant women in Latvia; NANS, National Adult Nutrition Survey; NDNS, National Diet and Nutrition Survey; NWSSP, Nutrition and Wellbeing of Secondary School Pupils; VELS, Verzehrsstudie zur Ermittlung der Lebensmittelaufnahme von Säuglingen und Kleinkindern für die Abschätzung eines akuten Toxizitätsrisikos durch Rückstände von Pflanzenschutzmitteln.

(a): A 48-hour dietary recall comprises two consecutive days.

(b): 5th or 95th percentile intakes calculated from fewer than 60 subjects require cautious interpretation, as the results may not be statistically robust (EFSA, 2011a) and, therefore, for these dietary surveys/age classes, the 5th and 95th percentile estimates will not be presented in the intake results.

(c): One subject was excluded from the dataset because only one 24-hour dietary recall day was available, i.e. final n = 990.

(d): The Swedish dietary records were introduced through the internet.
### Appendix B. Phosphorus intake in males in different surveys according to age classes and country

<table>
<thead>
<tr>
<th>Age class (b)</th>
<th>Country</th>
<th>Survey</th>
<th>Intake expressed in mg/day</th>
<th>Intake expressed in mg/MJ</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td><strong>Survey</strong></td>
<td><strong>n (a)</strong></td>
<td><strong>Average</strong></td>
</tr>
<tr>
<td>&lt; 1 year</td>
<td>Finland</td>
<td>DIPP_2001_2009</td>
<td>247</td>
<td>273</td>
</tr>
<tr>
<td></td>
<td>Germany</td>
<td>VELS</td>
<td>84</td>
<td>431</td>
</tr>
<tr>
<td></td>
<td>Italy</td>
<td>INRAN_SCAI_2005_06</td>
<td>9</td>
<td>326</td>
</tr>
<tr>
<td></td>
<td>United Kingdom</td>
<td>DNSIYC_2011</td>
<td>699</td>
<td>531</td>
</tr>
<tr>
<td>1 to &lt; 3 years</td>
<td>Finland</td>
<td>DIPP_2001_2009</td>
<td>245</td>
<td>719</td>
</tr>
<tr>
<td></td>
<td>Germany</td>
<td>VELS</td>
<td>174</td>
<td>699</td>
</tr>
<tr>
<td></td>
<td>Italy</td>
<td>INRAN_SCAI_2005_06</td>
<td>20</td>
<td>924</td>
</tr>
<tr>
<td></td>
<td>United Kingdom</td>
<td>DNSIYC_2011</td>
<td>663</td>
<td>871</td>
</tr>
<tr>
<td></td>
<td>United Kingdom</td>
<td>NDNS Rolling Programme Years 1–3</td>
<td>107</td>
<td>973</td>
</tr>
<tr>
<td>3 to &lt; 10 years</td>
<td>Finland</td>
<td>DIPP_2001_2009</td>
<td>381</td>
<td>1173</td>
</tr>
<tr>
<td></td>
<td>France</td>
<td>INCA2</td>
<td>239</td>
<td>1033</td>
</tr>
<tr>
<td></td>
<td>Germany</td>
<td>EsKiMo</td>
<td>426</td>
<td>1151</td>
</tr>
<tr>
<td></td>
<td>Germany</td>
<td>VELS</td>
<td>146</td>
<td>808</td>
</tr>
<tr>
<td></td>
<td>Italy</td>
<td>INRAN_SCAI_2005_06</td>
<td>94</td>
<td>1202</td>
</tr>
<tr>
<td></td>
<td>Netherlands</td>
<td>DNFCs 2007–2010</td>
<td>231</td>
<td>1146</td>
</tr>
<tr>
<td></td>
<td>United Kingdom</td>
<td>NDNS Rolling Programme Years 1–3</td>
<td>326</td>
<td>1076</td>
</tr>
<tr>
<td>10 to &lt; 18 years</td>
<td>Finland</td>
<td>NWSSP07_08</td>
<td>136</td>
<td>1601</td>
</tr>
<tr>
<td></td>
<td>France</td>
<td>INCA2</td>
<td>449</td>
<td>1243</td>
</tr>
<tr>
<td></td>
<td>Germany</td>
<td>EsKiMo</td>
<td>197</td>
<td>1225</td>
</tr>
<tr>
<td></td>
<td>Italy</td>
<td>INRAN_SCAI_2005_06</td>
<td>108</td>
<td>1494</td>
</tr>
<tr>
<td></td>
<td>Netherlands</td>
<td>DNFCs 2007–2010</td>
<td>566</td>
<td>1397</td>
</tr>
<tr>
<td></td>
<td>United Kingdom</td>
<td>NDNS Rolling Programme Years 1–3</td>
<td>340</td>
<td>1231</td>
</tr>
<tr>
<td>18 to &lt; 65 years</td>
<td>Finland</td>
<td>FINDIET2012</td>
<td>585</td>
<td>1614</td>
</tr>
<tr>
<td></td>
<td>France</td>
<td>INCA2</td>
<td>936</td>
<td>1403</td>
</tr>
<tr>
<td></td>
<td>Ireland</td>
<td>NANS_2012</td>
<td>634</td>
<td>1767</td>
</tr>
<tr>
<td></td>
<td>Italy</td>
<td>INRAN_SCAI_2005_06</td>
<td>1068</td>
<td>1378</td>
</tr>
<tr>
<td></td>
<td>Netherlands</td>
<td>DNFCs 2007–2010</td>
<td>1023</td>
<td>1671</td>
</tr>
<tr>
<td></td>
<td>Sweden</td>
<td>Riksmaten 2010</td>
<td>623</td>
<td>1692</td>
</tr>
<tr>
<td></td>
<td>United Kingdom</td>
<td>NDNS Rolling Programme Years 1–3</td>
<td>560</td>
<td>1448</td>
</tr>
</tbody>
</table>

Dietary Reference Values for phosphorus
Dietary Reference Values for phosphorus

EFSA Journal 2015;13(7):4185

<table>
<thead>
<tr>
<th>Age class</th>
<th>Country</th>
<th>Survey</th>
<th>n (a)</th>
<th>Intake expressed in mg/day</th>
<th>Intake expressed in mg/MJ</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Average</td>
<td>Median</td>
</tr>
<tr>
<td>65 to &lt; 75 years</td>
<td>Finland</td>
<td>FINDIET2012</td>
<td>210</td>
<td>1 426</td>
<td>1 367</td>
</tr>
<tr>
<td></td>
<td>France</td>
<td>INCA2</td>
<td>111</td>
<td>1 372</td>
<td>1 351</td>
</tr>
<tr>
<td></td>
<td>Ireland</td>
<td>NANS_2012</td>
<td>72</td>
<td>1 652</td>
<td>1 638</td>
</tr>
<tr>
<td></td>
<td>Italy</td>
<td>INRAN_SCAI_2005_06</td>
<td>133</td>
<td>1 311</td>
<td>1 315</td>
</tr>
<tr>
<td></td>
<td>Netherlands</td>
<td>DNFCS 2007–2010</td>
<td>91</td>
<td>1 478</td>
<td>1 448</td>
</tr>
<tr>
<td></td>
<td>Sweden</td>
<td>Riksmaten 2010</td>
<td>127</td>
<td>1 558</td>
<td>1 528</td>
</tr>
<tr>
<td></td>
<td>United Kingdom</td>
<td>NDNS Rolling Programme Years 1–3</td>
<td>75</td>
<td>1 498</td>
<td>1 479</td>
</tr>
<tr>
<td>≥ 75 years</td>
<td>France</td>
<td>INCA2</td>
<td>40</td>
<td>1 280</td>
<td>1 173</td>
</tr>
<tr>
<td></td>
<td>Ireland</td>
<td>NANS_2012</td>
<td>34</td>
<td>1 484</td>
<td>1 402</td>
</tr>
<tr>
<td></td>
<td>Italy</td>
<td>INRAN_SCAI_2005_06</td>
<td>69</td>
<td>1 332</td>
<td>1 279</td>
</tr>
<tr>
<td></td>
<td>Sweden</td>
<td>Riksmaten 2010</td>
<td>42</td>
<td>1 531</td>
<td>1 637</td>
</tr>
<tr>
<td></td>
<td>United Kingdom</td>
<td>NDNS Rolling Programme Years 1–3</td>
<td>56</td>
<td>1 253</td>
<td>1 169</td>
</tr>
</tbody>
</table>

P5, 5th percentile; P95, 95th percentile; DIPP, Type 1 Diabetes Prediction and Prevention survey; DNFCS, Dutch National Food Consumption Survey; DNSIYC, Diet and Nutrition Survey of Infants and Young Children; EsKiMo, Ernährungsstudie als KIGGS-Modul; FINDIET, the national dietary survey of Finland; INCA, Étude Individuelle Nationale des Consommations Alimentaires; INRAN_SCAI, Istituto Nazionale di Ricerca per gli Alimenti e la Nutrizione – Studio sui Consumi Alimentari in Italia; FC_PREGNANTWOMEN, food consumption of pregnant women in Latvia; NANS, National Adult Nutrition Survey; NDNS, National Diet and Nutrition Survey; NWSSP, Nutrition and Wellbeing of Secondary School Pupils; VELS, Verzehrsstudie zur Ermittlung der Lebensmittelauflaufnahme von Säuglingen und Kleinkindern für die Abschätzung eines akuten Toxizitätssrisikos durch Rückstände von Pflanzenschutzmitteln.

(a): Number of individuals in the population group.

(b): The proportions of breast-fed infants were 58 % in the Finnish survey, 40 % in the German survey, 44 % in the Italian survey and 21 % in the UK survey. Most infants were partially breast-fed. For the Italian and German surveys, breast milk intake estimates were derived from the number of breastfeeding events recorded per day multiplied by standard breast milk amounts consumed on an eating occasion at different age. For the UK survey, the amount of breast milk consumed was either directly quantified by the mother (expressed breast milk) or extrapolated from the duration of each breastfeeding event. As no information on the breastfeeding events were reported in the Finnish survey, breast milk intake was not taken into consideration in the intake estimates of Finnish infants.

(c): 5th or 95th percentile intakes calculated from fewer than 60 subjects require cautious interpretation, as the results may not be statistically robust (EFSA, 2011a) and, therefore, for these dietary surveys/age classes, the 5th and 95th percentile estimates will not be presented in the intake results.
Appendix C. Phosphorus intake in females in different surveys according to age classes and country

<table>
<thead>
<tr>
<th>Age class</th>
<th>Country</th>
<th>Survey</th>
<th>n (a)</th>
<th>Intake expressed in mg/day</th>
<th>Intake expressed in mg/MJ</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
<td>Average</td>
<td>Median</td>
<td>P5</td>
</tr>
<tr>
<td>&lt; 1 year</td>
<td>Finland</td>
<td>DIPP_2001_2009</td>
<td>253</td>
<td>265</td>
<td>264</td>
</tr>
<tr>
<td></td>
<td>Germany</td>
<td>VELS</td>
<td>75</td>
<td>368</td>
<td>354</td>
</tr>
<tr>
<td></td>
<td>Italy</td>
<td>INRAN_SCAI_2005_06</td>
<td>7</td>
<td>447</td>
<td>509</td>
</tr>
<tr>
<td></td>
<td>United Kingdom</td>
<td>DNSIYC_2011</td>
<td>670</td>
<td>480</td>
<td>448</td>
</tr>
<tr>
<td>1 to &lt; 3 years</td>
<td>Finland</td>
<td>DIPP_2001_2009</td>
<td>255</td>
<td>711</td>
<td>706</td>
</tr>
<tr>
<td></td>
<td>Germany</td>
<td>VELS</td>
<td>174</td>
<td>641</td>
<td>645</td>
</tr>
<tr>
<td></td>
<td>Italy</td>
<td>INRAN_SCAI_2005_06</td>
<td>16</td>
<td>890</td>
<td>846</td>
</tr>
<tr>
<td></td>
<td>United Kingdom</td>
<td>DNSIYC_2011</td>
<td>651</td>
<td>815</td>
<td>802</td>
</tr>
<tr>
<td></td>
<td>United Kingdom</td>
<td>NDNS Rolling Programme Years 1–3</td>
<td>78</td>
<td>863</td>
<td>856</td>
</tr>
<tr>
<td>3 to 10 years</td>
<td>Finland</td>
<td>DIPP_2001_2009</td>
<td>369</td>
<td>1086</td>
<td>1068</td>
</tr>
<tr>
<td></td>
<td>France</td>
<td>INCA2</td>
<td>243</td>
<td>925</td>
<td>901</td>
</tr>
<tr>
<td></td>
<td>Germany</td>
<td>EsKiMo</td>
<td>409</td>
<td>1056</td>
<td>1032</td>
</tr>
<tr>
<td></td>
<td>Germany</td>
<td>VELS</td>
<td>147</td>
<td>750</td>
<td>742</td>
</tr>
<tr>
<td></td>
<td>Italy</td>
<td>INRAN_SCAI_2005_06</td>
<td>99</td>
<td>1155</td>
<td>1138</td>
</tr>
<tr>
<td></td>
<td>Netherlands</td>
<td>DNFCs 2007–2010</td>
<td>216</td>
<td>1080</td>
<td>1033</td>
</tr>
<tr>
<td></td>
<td>United Kingdom</td>
<td>NDNS Rolling Programme Years 1–3</td>
<td>325</td>
<td>991</td>
<td>980</td>
</tr>
<tr>
<td>10 to &lt; 18 years</td>
<td>Finland</td>
<td>NWSSP07_08</td>
<td>170</td>
<td>1264</td>
<td>1255</td>
</tr>
<tr>
<td></td>
<td>France</td>
<td>INCA2</td>
<td>524</td>
<td>992</td>
<td>983</td>
</tr>
<tr>
<td></td>
<td>Germany</td>
<td>EsKiMo</td>
<td>196</td>
<td>1448</td>
<td>1130</td>
</tr>
<tr>
<td></td>
<td>Italy</td>
<td>INRAN_SCAI_2005_06</td>
<td>139</td>
<td>1226</td>
<td>1217</td>
</tr>
<tr>
<td></td>
<td>Latvia (d)</td>
<td>FC_PREGNANTWOMEN_2011</td>
<td>12</td>
<td>1561</td>
<td>1458</td>
</tr>
<tr>
<td></td>
<td>Netherlands</td>
<td>DNFCs 2007–2010</td>
<td>576</td>
<td>1167</td>
<td>1138</td>
</tr>
<tr>
<td></td>
<td>United Kingdom</td>
<td>NDNS Rolling Programme Years 1–3</td>
<td>326</td>
<td>990</td>
<td>977</td>
</tr>
<tr>
<td>18 to &lt; 65 years</td>
<td>Finland</td>
<td>FINDIET2012</td>
<td>710</td>
<td>1293</td>
<td>1242</td>
</tr>
<tr>
<td></td>
<td>France</td>
<td>INCA2</td>
<td>1340</td>
<td>1084</td>
<td>1060</td>
</tr>
<tr>
<td></td>
<td>Ireland</td>
<td>NANS_2012</td>
<td>640</td>
<td>1302</td>
<td>1274</td>
</tr>
<tr>
<td></td>
<td>Italy</td>
<td>INRAN_SCAI_2005_06</td>
<td>1245</td>
<td>1511</td>
<td>1124</td>
</tr>
<tr>
<td></td>
<td>Latvia (d)</td>
<td>FC_PREGNANTWOMEN_2011</td>
<td>990</td>
<td>1541</td>
<td>1443</td>
</tr>
<tr>
<td></td>
<td>Netherlands</td>
<td>DNFCs 2007–2010</td>
<td>1034</td>
<td>1279</td>
<td>1241</td>
</tr>
<tr>
<td></td>
<td>Sweden</td>
<td>Riksmaten 2010</td>
<td>807</td>
<td>1336</td>
<td>1301</td>
</tr>
<tr>
<td></td>
<td>United Kingdom</td>
<td>NDNS Rolling Programme Years 1–3</td>
<td>706</td>
<td>1127</td>
<td>1106</td>
</tr>
<tr>
<td>Age class</td>
<td>Country</td>
<td>Survey</td>
<td>n (a)</td>
<td>Intake expressed in mg/day</td>
<td>Intake expressed in mg/MJ</td>
</tr>
<tr>
<td>-----------</td>
<td>-------------</td>
<td>---------------------------------</td>
<td>-------</td>
<td>---------------------------</td>
<td>--------------------------</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Average</td>
<td>Median</td>
</tr>
<tr>
<td>65 to &lt; 75 years</td>
<td>Finland</td>
<td>FINDIET2012</td>
<td>203</td>
<td>1 153</td>
<td>1 140</td>
</tr>
<tr>
<td></td>
<td>France</td>
<td>INCA2</td>
<td>153</td>
<td>1 050</td>
<td>1 034</td>
</tr>
<tr>
<td></td>
<td>Ireland</td>
<td>NANS_2012</td>
<td>77</td>
<td>1 372</td>
<td>1 333</td>
</tr>
<tr>
<td></td>
<td>Italy</td>
<td>INRAN_SCAI_2005_06</td>
<td>157</td>
<td>1 098</td>
<td>1 082</td>
</tr>
<tr>
<td></td>
<td>Netherlands</td>
<td>DNFCS 2007–2010</td>
<td>82</td>
<td>1 181</td>
<td>1 148</td>
</tr>
<tr>
<td></td>
<td>Sweden</td>
<td>Riksmaten 2010</td>
<td>168</td>
<td>1 310</td>
<td>1 272</td>
</tr>
<tr>
<td></td>
<td>United Kingdom</td>
<td>NDNS Rolling Programme Years 1–3</td>
<td>91</td>
<td>1 145</td>
<td>1 144</td>
</tr>
<tr>
<td>≥ 75 years</td>
<td>France</td>
<td>INCA2</td>
<td>44</td>
<td>1 000</td>
<td>975</td>
</tr>
<tr>
<td></td>
<td>Ireland</td>
<td>NANS_2012</td>
<td>43</td>
<td>1 294</td>
<td>1 275</td>
</tr>
<tr>
<td></td>
<td>Italy</td>
<td>INRAN_SCAI_2005_06</td>
<td>159</td>
<td>1 075</td>
<td>1 080</td>
</tr>
<tr>
<td></td>
<td>Sweden</td>
<td>Riksmaten 2010</td>
<td>30</td>
<td>1 330</td>
<td>1 316</td>
</tr>
<tr>
<td></td>
<td>United Kingdom</td>
<td>NDNS Rolling Programme Years 1–3</td>
<td>83</td>
<td>1 162</td>
<td>1 139</td>
</tr>
</tbody>
</table>

P5, 5th percentile; P95, 95th percentile; DIPP, Type 1 Diabetes Prediction and Prevention survey; DNFCs, Dutch National Food Consumption Survey; DNSIYC, Diet and Nutrition Survey of Infants and Young Children; EsKiMo, Ernährungsstudie als KIGGS-Modul; FINDIET, the national dietary survey of Finland; INCA, Étude Individuelle Nationale des Consommations Alimentaires; INRAN-SCAI, Istituto Nazionale di Ricerca per gli Alimenti e la Nutrizione – Studio sui Consumi Alimentari in Italia; FC_PREGNANTWOMEN, food consumption of pregnant women in Latvia; NANS, National Adult Nutrition Survey; NDNS, National Diet and Nutrition Survey; NWSSP, Nutrition and Wellbeing of Secondary School Pupils; VELS, Verzehrsstudie zur Ermittlung der Lebensmittelaufnahme von Säuglingen und Kleinkindern für die Abschätzung eines akuten Toxizitätsrisikos durch Rückstände von Pflanzenschutzmitteln.

(a): Number of individuals in the population group.
(b): The proportions of breast-fed infants were 58 % in the Finnish survey, 40 % in the German survey, 44 % in the Italian survey and 21 % in the UK survey. Most infants were partially breast-fed. For the Italian and German surveys, breast milk intake estimates were derived from the number of breastfeeding events recorded per day multiplied by standard breast milk amounts consumed on an eating occasion at different age. For the UK survey, the amount of breast milk consumed was either directly quantified by the mother (expressed breast milk) or extrapolated from the duration of each breastfeeding event. As no information on the breastfeeding events were reported in the Finnish survey, breast milk intake was not taken into consideration in the intake estimates of Finnish infants.
(c): 5th or 95th percentile intakes calculated from fewer than 60 subjects require cautious interpretation, as the results may not be statistically robust (EFSA, 2011a) and, therefore, for these dietary surveys/age classes, the 5th and 95th percentile estimates will not be presented in the intake results.
(d): Pregnant women only.
Appendix D. Minimum and maximum percentage contribution of different food groups (FoodEx2 level 1) to phosphorus intake in males

<table>
<thead>
<tr>
<th>Food groups</th>
<th>&lt; 1 year</th>
<th>1 to &lt; 3 years</th>
<th>3 to &lt; 10 years</th>
<th>10 to &lt; 18 years</th>
<th>Age &lt; 18 to 65 years</th>
<th>Age 65 to &lt; 75 years</th>
<th>≥ 75 years</th>
</tr>
</thead>
<tbody>
<tr>
<td>Additives, flavours, baking and processing aids</td>
<td>&lt; 1</td>
<td>&lt; 1</td>
<td>0–1</td>
<td>0–1</td>
<td>0</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>Alcoholic beverages</td>
<td>&lt; 1</td>
<td>&lt; 1</td>
<td>&lt; 1</td>
<td>&lt; 1</td>
<td>&lt; 1</td>
<td>2–5</td>
<td>1–4</td>
</tr>
<tr>
<td>Animal and vegetable fats and oils</td>
<td>&lt; 1</td>
<td>&lt; 1</td>
<td>&lt; 1–1</td>
<td>&lt; 1</td>
<td>&lt; 1</td>
<td>&lt; 1–1</td>
<td>&lt; 1–1</td>
</tr>
<tr>
<td>Coffee, cocoa, tea and infusions</td>
<td>&lt; 1</td>
<td>&lt; 1–1</td>
<td>&lt; 1–2</td>
<td>1–2</td>
<td>1–6</td>
<td>1–6</td>
<td>1–7</td>
</tr>
<tr>
<td>Composite dishes</td>
<td>&lt; 1–3</td>
<td>&lt; 1–8</td>
<td>&lt; 1–9</td>
<td>&lt; 1–13</td>
<td>&lt; 1–12</td>
<td>1–10</td>
<td>&lt; 1–10</td>
</tr>
<tr>
<td>Eggs and egg products</td>
<td>&lt; 1–1</td>
<td>1–2</td>
<td>1–4</td>
<td>1–4</td>
<td>1–4</td>
<td>1–4</td>
<td>1–3</td>
</tr>
<tr>
<td>Fish, seafood, amphibians, reptiles and invertebrates</td>
<td>&lt; 1–1</td>
<td>1–6</td>
<td>1–5</td>
<td>1–6</td>
<td>2–7</td>
<td>3–9</td>
<td>5–9</td>
</tr>
<tr>
<td>Food products for young population</td>
<td>26–50</td>
<td>2–8</td>
<td>&lt; 1–1</td>
<td>&lt; 1</td>
<td>&lt; 1</td>
<td>–</td>
<td>–</td>
</tr>
<tr>
<td>Fruit and fruit products</td>
<td>1–6</td>
<td>2–3</td>
<td>1–2</td>
<td>1–2</td>
<td>&lt; 1–1</td>
<td>&lt; 1–1</td>
<td>&lt; 1–1</td>
</tr>
<tr>
<td>Fruit and vegetable juices and nectars</td>
<td>&lt; 1–1</td>
<td>&lt; 1–1</td>
<td>1–2</td>
<td>1–2</td>
<td>&lt; 1–1</td>
<td>&lt; 1–1</td>
<td>&lt; 1–1</td>
</tr>
<tr>
<td>Human milk</td>
<td>&lt; 1–16</td>
<td>&lt; 1</td>
<td>–</td>
<td>–</td>
<td>–</td>
<td>–</td>
<td>–</td>
</tr>
<tr>
<td>Legumes, nuts, oilseeds and spices</td>
<td>&lt; 1–2</td>
<td>1–3</td>
<td>1–4</td>
<td>1–3</td>
<td>2–4</td>
<td>1–4</td>
<td>1–3</td>
</tr>
<tr>
<td>Products for non-standard diets, food imitates and food supplements or fortifying agents</td>
<td>0–1</td>
<td>0–1</td>
<td>0–1</td>
<td>&lt; 1</td>
<td>&lt; 1–1</td>
<td>&lt; 1–1</td>
<td>0–1</td>
</tr>
<tr>
<td>Seasoning, sauces and condiments</td>
<td>&lt; 1–1</td>
<td>&lt; 1–1</td>
<td>&lt; 1–1</td>
<td>&lt; 1–1</td>
<td>&lt; 1–1</td>
<td>&lt; 1–1</td>
<td>&lt; 1–1</td>
</tr>
<tr>
<td>Starchy roots or tubers and products thereof, sugar plants</td>
<td>&lt; 1–6</td>
<td>1–5</td>
<td>2–6</td>
<td>2–7</td>
<td>2–6</td>
<td>2–5</td>
<td>3–5</td>
</tr>
<tr>
<td>Sugar, confectionery and water-based sweet desserts</td>
<td>&lt; 1</td>
<td>&lt; 1–3</td>
<td>1–5</td>
<td>1–5</td>
<td>&lt; 1–1</td>
<td>&lt; 1–1</td>
<td>&lt; 1–1</td>
</tr>
<tr>
<td>Vegetables and vegetable products</td>
<td>1–7</td>
<td>2–3</td>
<td>2–4</td>
<td>2–5</td>
<td>2–6</td>
<td>2–6</td>
<td>2–6</td>
</tr>
<tr>
<td>Water and water-based beverages</td>
<td>&lt; 1</td>
<td>&lt; 1–1</td>
<td>&lt; 1–2</td>
<td>1–4</td>
<td>&lt; 1–3</td>
<td>&lt; 1–1</td>
<td>&lt; 1</td>
</tr>
</tbody>
</table>

“<...” means that there was no consumption event of the food group for the age and sex group considered, whereas “0” means that there were some consumption events, but that the food group does not contribute to phosphorus intake in the age and sex group considered.
### Appendix E. Minimum and maximum percentage contribution of different food groups (FoodEx2 level 1) to phosphorus intake in females

<table>
<thead>
<tr>
<th>Food groups</th>
<th>&lt; 1 year</th>
<th>1 to &lt; 3 years</th>
<th>3 to &lt; 10 years</th>
<th>10 to &lt; 18 years</th>
<th>Age 18 to &lt; 65 years</th>
<th>65 to &lt; 75 years</th>
<th>≥ 75 years</th>
</tr>
</thead>
<tbody>
<tr>
<td>Additives, flavours, baking and processing aids</td>
<td>&lt; 1</td>
<td>0</td>
<td>0–1</td>
<td>0–1</td>
<td>0</td>
<td>&lt;1</td>
<td>0</td>
</tr>
<tr>
<td>Alcoholic beverages</td>
<td>&lt; 1</td>
<td>&lt; 1</td>
<td>&lt; 1</td>
<td>&lt; 1</td>
<td>&lt; 1–2</td>
<td>&lt; 1–1</td>
<td>&lt; 1–1</td>
</tr>
<tr>
<td>Animal and vegetable fats and oils</td>
<td>&lt; 1</td>
<td>&lt; 1</td>
<td>&lt; 1–1</td>
<td>&lt; 1–1</td>
<td>&lt; 1–1</td>
<td>&lt; 1–1</td>
<td>&lt; 1–1</td>
</tr>
<tr>
<td>Coffee, cocoa, tea and infusions</td>
<td>&lt; 1–3</td>
<td>&lt; 1–5</td>
<td>&lt; 1–2</td>
<td>&lt; 1–2</td>
<td>1–7</td>
<td>1–7</td>
<td>1–7</td>
</tr>
<tr>
<td>Composite dishes</td>
<td>&lt; 1–3</td>
<td>&lt; 1–7</td>
<td>&lt; 1–9</td>
<td>&lt; 1–13</td>
<td>1–12</td>
<td>&lt; 1–9</td>
<td>&lt; 1–10</td>
</tr>
<tr>
<td>Eggs and egg products</td>
<td>&lt; 1–1</td>
<td>1–2</td>
<td>1–4</td>
<td>1–4</td>
<td>1–3</td>
<td>1–3</td>
<td>1–4</td>
</tr>
<tr>
<td>Fish, seafood, amphibians, reptiles and invertebrates</td>
<td>&lt; 1–2</td>
<td>1–7</td>
<td>&lt; 1–5</td>
<td>1–7</td>
<td>2–7</td>
<td>3–9</td>
<td>3–8</td>
</tr>
<tr>
<td>Food products for young population</td>
<td>23–60</td>
<td>2–9</td>
<td>&lt; 1</td>
<td>&lt; 1</td>
<td>&lt; 1</td>
<td>–</td>
<td>&lt; 1</td>
</tr>
<tr>
<td>Fruit and fruit products</td>
<td>2–5</td>
<td>2–3</td>
<td>1–2</td>
<td>1–3</td>
<td>1–3</td>
<td>2–4</td>
<td>2–4</td>
</tr>
<tr>
<td>Fruit and vegetable juices and nectars</td>
<td>&lt; 1–1</td>
<td>&lt; 1–1</td>
<td>1–2</td>
<td>1–2</td>
<td>&lt; 1–1</td>
<td>&lt; 1–1</td>
<td>&lt; 1–1</td>
</tr>
<tr>
<td>Grains and grain-based products</td>
<td>10–16</td>
<td>17–28</td>
<td>17–33</td>
<td>21–33</td>
<td>19–38</td>
<td>18–32</td>
<td>17–33</td>
</tr>
<tr>
<td>Human milk</td>
<td>&lt; 1–6</td>
<td>&lt; 1</td>
<td>–</td>
<td>–</td>
<td>–</td>
<td>–</td>
<td>–</td>
</tr>
<tr>
<td>Legumes, nuts, oilseeds and spices</td>
<td>&lt; 1–3</td>
<td>1–3</td>
<td>1–4</td>
<td>1–3</td>
<td>2–4</td>
<td>2–4</td>
<td>2–3</td>
</tr>
<tr>
<td>Meat and meat products</td>
<td>1–8</td>
<td>5–10</td>
<td>8–19</td>
<td>11–22</td>
<td>12–21</td>
<td>12–20</td>
<td>10–19</td>
</tr>
<tr>
<td>Products for non-standard diets, food imitates and food supplements or fortifying agents</td>
<td>0</td>
<td>0–1</td>
<td>0–1</td>
<td>0–1</td>
<td>0–1</td>
<td>0–1</td>
<td>0–1</td>
</tr>
<tr>
<td>Seasoning, sauces and condiments</td>
<td>&lt; 1</td>
<td>&lt; 1–1</td>
<td>&lt; 1–1</td>
<td>&lt; 1–1</td>
<td>&lt; 1–1</td>
<td>&lt; 1–1</td>
<td>&lt; 1–1</td>
</tr>
<tr>
<td>Starchy roots or tubers and products thereof, sugar plants</td>
<td>1–6</td>
<td>2–4</td>
<td>2–6</td>
<td>2–8</td>
<td>2–6</td>
<td>2–5</td>
<td>2–4</td>
</tr>
<tr>
<td>Sugar, confectionery and water-based sweet desserts</td>
<td>&lt; 1–1</td>
<td>&lt; 1–2</td>
<td>1–5</td>
<td>1–5</td>
<td>&lt; 1–2</td>
<td>&lt; 1–1</td>
<td>&lt; 1–1</td>
</tr>
<tr>
<td>Vegetables and vegetable products</td>
<td>2–7</td>
<td>2–3</td>
<td>2–4</td>
<td>3–5</td>
<td>2–7</td>
<td>2–7</td>
<td>2–6</td>
</tr>
<tr>
<td>Water and water-based beverages</td>
<td>&lt; 1</td>
<td>&lt; 1–1</td>
<td>&lt; 1–2</td>
<td>&lt; 1–3</td>
<td>&lt; 1–2</td>
<td>&lt; 1</td>
<td>&lt; 1</td>
</tr>
</tbody>
</table>

“...” means that there was no consumption event of the food group for the age and sex group considered, whereas “0” means that there were some consumption events, but that the food group does not contribute to phosphorus intake in the age and sex group considered.
Appendix F. Calculations for deriving Adequate Intakes for phosphorus

The below calculations are based on the AI (for infants aged 7–11 months) and the PRIs (for all other ages) for calcium (EFSA NDA Panel, 2015), as well as on atomic masses for calcium of 40.08, and of 30.97 for phosphorus. A molar ratio of 1.4:1 to 1.9:1 was used (Sections 2.3.7 and 6.1).

<table>
<thead>
<tr>
<th>Age</th>
<th>AI for calcium (mg/day)</th>
<th>PRI for calcium (mg/day)</th>
<th>Calculated value for phosphorus (mg/day) based on a ratio of 1.9:1</th>
<th>Calculated value for phosphorus (mg/day) based on a ratio of 1.4:1</th>
</tr>
</thead>
<tbody>
<tr>
<td>7–11 months</td>
<td>280</td>
<td>114</td>
<td>155</td>
<td></td>
</tr>
<tr>
<td>1–3 years</td>
<td>450</td>
<td>183</td>
<td>248</td>
<td></td>
</tr>
<tr>
<td>4–10 years</td>
<td>800</td>
<td>325</td>
<td>442</td>
<td></td>
</tr>
<tr>
<td>11–17 years</td>
<td>1 150</td>
<td>468</td>
<td>635</td>
<td></td>
</tr>
<tr>
<td>Adults 18–24 years (a)</td>
<td>1 000</td>
<td>407</td>
<td>552</td>
<td></td>
</tr>
<tr>
<td>Adults ≥ 25 years (a)</td>
<td>950</td>
<td>386</td>
<td>524</td>
<td></td>
</tr>
</tbody>
</table>

AI, Adequate Intake; PRI, Population Reference Intake.
(a): Including pregnant and lactating women.
ABBREVIATIONS

1,25(OH)₂D  1,25-dihydroxy-vitamin D (the active metabolite of vitamin D)

Afssa  Agence française de sécurité sanitaire des aliments

AI  Adequate Intake

AR  Average Requirement

ATBC  Alpha-Tocopherol Beta-Carotene Cancer Prevention

ATP  adenosine triphosphate

BMC  bone mineral content

BMD  bone mineral density

cAMP  cyclic adenosine monophosphate

cGMP  cyclic guanosine monophosphate

COMA  Committee on Medical Aspects of Food Policy

CI  confidence interval

CV  coefficient of variation

CVD  cardiovascular disease

D-A-CH  Deutschland–Austria–Confoederatio Helvetica

DH  UK Department of Health

DIPP  Type 1 Diabetes Prediction and Prevention

DNFCS  Dutch National Food Consumption Survey

DNSIYC  Diet and Nutrition Survey of Infants and Young Children

DRV  Dietary Reference Value

DXA  dual-energy X-ray absorptiometry

EAR  Estimated Average Requirement

EsKiMo  Ernährungsstudie als KIGGS-Modul

FAO  Food and Agriculture Organization of the United Nations

FC_PREGNANTWOMEN  food consumption of pregnant women in Latvia

FFQ  food frequency questionnaire
<table>
<thead>
<tr>
<th>Acronym</th>
<th>Explanation</th>
</tr>
</thead>
<tbody>
<tr>
<td>FGF-23</td>
<td>fibroblast growth factor-23</td>
</tr>
<tr>
<td>FINDIET</td>
<td>the national dietary survey of Finland</td>
</tr>
<tr>
<td>HR</td>
<td>hazard ratio</td>
</tr>
<tr>
<td>INCA</td>
<td>Étude Individuelle Nationale des Consommations Alimentaires</td>
</tr>
<tr>
<td>INRAN-SCAI</td>
<td>Istituto Nazionale di Ricerca per gli Alimenti e la Nutrizione – Studio sui Consumi Alimentari in Italia</td>
</tr>
<tr>
<td>IOM</td>
<td>US Institute of Medicine of the National Academy of Sciences</td>
</tr>
<tr>
<td>NANS</td>
<td>National Adult Nutrition Survey</td>
</tr>
<tr>
<td>NaPi-IIa, NaPi-IIb, NaPi-IIc</td>
<td>sodium-dependent phosphate transporters</td>
</tr>
<tr>
<td>NDNS</td>
<td>National Diet and Nutrition Survey</td>
</tr>
<tr>
<td>NHANES</td>
<td>National Health and Nutrition Examination Survey</td>
</tr>
<tr>
<td>NNR</td>
<td>Nordic Nutrition Recommendations</td>
</tr>
<tr>
<td>NWSSP</td>
<td>Nutrition and Wellbeing of Secondary School Pupils</td>
</tr>
<tr>
<td>PRI</td>
<td>Population Reference Intake</td>
</tr>
<tr>
<td>PTH</td>
<td>parathyroid hormone</td>
</tr>
<tr>
<td>RDA</td>
<td>Recommended Dietary Allowance</td>
</tr>
<tr>
<td>RI</td>
<td>Recommended Intake</td>
</tr>
<tr>
<td>RNI</td>
<td>Reference Nutrient Intake</td>
</tr>
<tr>
<td>RR</td>
<td>relative risk</td>
</tr>
<tr>
<td>SCF</td>
<td>Scientific Committee for Food</td>
</tr>
<tr>
<td>SD</td>
<td>standard deviation</td>
</tr>
<tr>
<td>sFRP-4</td>
<td>secreted frizzled-related protein 4</td>
</tr>
<tr>
<td>SU.VI.MAX</td>
<td>SUpplémentation en VItamines et Minéraux Anti-oXydants</td>
</tr>
<tr>
<td>UL</td>
<td>Tolerable Upper Intake Level</td>
</tr>
<tr>
<td>VELS</td>
<td>Verzehrsstudie zur Ermittlung der Lebensmittelsaufnahme von Säuglingen und Kleinkindern für die Abschätzung eines akuten Toxizitätsrisikos durch Rückstände von Pflanzenschutzmitteln</td>
</tr>
<tr>
<td>WHO</td>
<td>World Health Organization</td>
</tr>
</tbody>
</table>